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1. Introduction 
 
1.1 Filariasis 
 
Infections with filarial nematodes affect more than 150 million people 
mainly in the tropics. Official estimates state that a total of 120 million 
people are infected with the causative agents of lymphatic filariasis (LF), 
Wuchereria bancrofti, Brugia malayi and Brugia timori and >1.34 billion 
people are at risk of infection living in one of the 81 endemic countries 
[1]. For Onchocerca volvulus, which is endemic in 19 african countires, 
>102 million people are at risk of infection [2] with approximately 37 
million people being already infected [3].  
 
1.2 Lymphatic filariasis (LF) 
 
Lymphatic filariasis is endemic in 81 countries of the world. These 
comprise sub-Saharan Africa (plus a small focus in the Nile Delta), South 
Asia (with a large population infected in the Indian subcontinent), 
Southeast Asia, many tropical Pacific islands and some areas in South 
America (Figure 1) [4].  
More than 1 billion people are living in endemic areas and thus are at risk 
to acquire infection [5]. Infective third stage larvae (L3) are transmitted 
by insect vectors, Anopheles in rural African and Culex in urban/sub-
saharan areas. In Southeast Asia the vectors are mainly Mansonia and 
Aedes spp.. 
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Figure 1 Global distribution of lymphatic filariasis                 www.who.int                  
 
The first stage larvae (Microfilariae, Mf) are picked up by the vector and 
develop with two moults into infective L3 (Figure 2). During a blood meal, 
these are deposited on the skin surface and actively invade the host 
through the biting area. There, the L3 develop to the L4 stage and finally 
to adult worms. Adult filarial parasites are sexually dimorphic and reside in 
the lymphatic vessels, where they mate and produce thousands of Mf for 
up to eight years. In adult men, W. bancrofti [6-8] but not B. malayi [9] 
are usually seen in the scrotal areas (Figure 3) where they can be 
visualized via ultrasonography (USG) in dilated lymphatics. 
After 6-12 months, Mf can be detected in approximately 50% of the 
infected individuals. They show a periodicity in adaption to the preferred 
biting hours of their vector. Culex, Anopheles and Mansonia spp. are 
vectors active at night whereas Aedes spp. are daytime vectors. 
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Figure 2 Life cycle of W. bancrofti, causative agent of LF 
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Figure 3 Hydrocele and lymphedema     Pictures © Sabine Mand 
 
Except for the rare disease of tropical pulmonary eosinophilia, which is a 
hyper-reactivity to Mf while they are passing through the lung, Mf do not 
induce major disease. The major pathologies of LF are attributed to death 
and destruction of adult worms within the lymphatic vessels. Clinical 
studies have also implicated a role for secondary opportunistic infections 
along with other cofactors in advancing the chronic pathologies of LF [10]. 
The pathology in LF has a spectrum of clinical states with two major poles. 
One pole is represented by microfilaremic patients with high parasite 
numbers and down regulated cell-mediated immune responses, and the 
other by patients with lymphedema (LE) or hydrocele (Figure 1) who 
typically have few or no parasites but specific immune reactions [11].  
Approximately 40 million people suffer from the stigmatizing and disabling 
clinical manifestations of the disease, including 15 million who have 
lymphoedema (elephantiasis) and 25 million men who have urogenital 
swelling, principally scrotal hydrocele [1]. LE and hydrocele are not 
mutually exclusive and both involve dilation of the lymphatic vessels and 
flow of lymph into surrounding tissues, indicating a shared pathogenesis. 
Both pathologies develop progressively and not all affected individuals will 
progress to the most severe form of pathology. 
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1.3 Onchocerciasis 
The parasite Onchocerca volvulus is transmitted by small blackflies of the 
genus Simulium, which breed in fast-flowing, highly oxygenated rivers and 
streams [12]. An infected blackfly deposits one or more infective L3 which 
have developed within 10 days from Mf acquired from other humans 
during a preceding blood meal. The L3 develop into adults within a year 
and accumulate in subcutaneous or deep nodules, so-called 
onchocercomata (Figure 4). 
 
 
Figure 4 Life cycle O.volvulus, causative agent of onchocerciasis 
       Pictures © D. W. Büttner, S. Mand and S. Specht 
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In onchocerciasis, Mf are born from viviparous females and induce disease 
symptoms, including chronic dermatitis and skin atrophy, lymphadenitis 
and fibrosis. The Mf migrate through the nodular tissue and then to the 
dermal part of the skin where they can be taken up by blackflies during a 
blood meal. Invasion of the cornea by Mf leads to corneal opacity and 
thus, can lead to blindness. Onchocerciasis is the second most common 
cause of blindness induced by an infectious agent in the developing world. 
About 50% of adults are affected by blindness in some West african 
Savannah communities with an estimated economic loss of US$ 30 Million 
[13]. The WHO estimated in 1995 that 800,000 people are visually 
impaired and 270,000 are blind due to infection with O. volvulus [14]. 
Very important, although second to blindness, are the various forms of 
dermatitis that Mf induce in the skin. In a highly infected individual with 
more than five palpable nodules, one can calculate a daily turnover of 
50,000 Mf [15]. The females produce millions of Mf during their lifetime, 
which lasts up to 14 years [16]. Thus, infected persons are constantly 
exposed to worm antigenic molecules. O. volvulus develops only in human 
and presumably has no animal reservoir. 
The disease is most closely associated with West and Central Africa with 
19 endemic countries, but it is also prevalent in Yemen and six countries 
in Latin America (Figure 5) [2, 13].  
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Figure 5 Global distibution of onchocerciasis in Africa and America. 
Endemic areas for onchocerciasis are in red, co-endemic areas for onchocerciasis and LF 
are in orange. 
 
1.4 Treatment strategies 
The World Health Assembly, in its 1997 resolution WHA 50.35, has called 
for the elimination of onchocerciasis and lymphatic filariasis as public 
health problems [17]. There are three standard drugs in use for filarial 
infections: diethylcarbamazine (DEC), albendazole (ALB) and ivermectin 
(IVM). DEC is the oldest of the three and is still used for LF, since it has a 
strong microfilaricidal and partial macrofilaricidal effect [18]. In individuals 
with infection, adverse reactions can arise after DEC is given. Reactions 
are associated with the rapid killing of Mf wich induces systemic 
inflamation caused by release of Wolbachia endobacteria [19]. DEC is 
known to cause irreversible ocular damage in onchocerciasis patients with 
moderate-to-high Mf counts. This has precluded its use for onchocerciasis 
as well as for LF or loiasis in areas where onchocerciasis is coendemic.  
www.mectizan.org/maps.asp 
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A broad-spectrum anthelmintic which is effective against nematodes, 
flatworms and cestodes is ALB [20]. The drug inhibits polymerisation of β-
tubulin and microtubule formation. 
Ivermectin, a macrocyclic lactone [21], was introduced as treatment for 
onchocerciasis in the 1980s. It acts through inhibition of glutamate-gated 
chloride channels of Mf, effectively immobilizing them so that they are 
carried with the lymphatic flow from their usual locations into the regional 
lymph nodes. Since Mf are killed away from the eye, there is no ocular 
damage following IVM.  
Mass drug administration (MDA) is the major tool of intervention in the 
different control programs: the African Programme of Onchocerciasis 
Control (APOC) [2, 22-24], the Onchocerciasis Elimination Programme for 
the Americas (OEPA) [24, 25] and the Global Programme to Eliminate 
Lymphatic Filariasis (GPELF) [1, 5, 26]. All programs use different 
treatment regimes ranging from a single dose of IVM per year (APOC) or 
IVM and ALB (GPELF) in Africa to twice-yearly application of IVM (OEPA). 
The general idea in mass chemotherapy is to abolish Mf in the skin and 
blood in a large enough proportion of the population so that the cycle of 
transmission is inhibited or blocked. However, even after the end of 
transmission, mass treatment has to continue at least as long as adult 
worms survive in humans (up to 14 years) [27]. A major problem with the 
current control strategy is that while IVM and DEC kill Mf, they do not 
effectively kill adult worms nor permanently stop Mf production.  
For almost 30 years, it has been known that filarial nematodes contain 
endosymbiotic bacteria. The endobacteria are found in the hypodermis of 
male and female worms, and in oocytes, embryos and all larval stages 
(Figure 6). Apart from many animal filarial species, endobacteria are 
present in the human filariae W. bancrofti, Brugia spp. and O. volvulus 
[28, 29], Mansonella perstans [30] and M. ozzardi [31], but not in L. loa 
[32, 33]. 
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These endosymbionts were classified at the molecular level to be of the 
genus Wolbachia, which are also common endosymbionts of arthropods 
[34, 35].  
In filarial species that harbour Wolbachia as endosymbionts, it seems to 
be a mutualistic adaption that has lasted for many million years [36], with 
vertical transmission of the bacteria via oocytes from one worm 
generation to the next. 
 
 
 
           Picture © by D. W. Büttner 
Figure 6 Female O. volvulus worm with Wolbachia endosymbionts  
(purple colour) 
U: Uterus             
H: Hypodermis 
 
The efficacy of tetracycline antibiotics to deplete the Wolbachia 
endosymbionts, which are essential for larval moulting and adult female 
worm fertility in those filarial species that harbour them, was first shown 
in several animal models of filariasis [37-39]. On the molecular level, 
there is circumstantial evidence that one of the metabolic pathways which 
the Wolbachia provide to the worm may be the synthesis of nucleotides 
because filarial worms lack most of the genes necessary for nucleotide 
U 
H 
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synthesis [36], while Wolbachia have kept all of them [40]. Lack of 
nucleotide synthesis would particularly affect cell division in embryos, and 
indeed this is the first parasitological feature that can be observed after 
Wolbachia depletion [41]. Trials on doxycycline involving humans have 
been ongoing for more than 10 years [41-49]. The first human trial 
involved onchocerciasis patients that were treated daily with a dose of 100 
mg doxycycline for 6 weeks, followed by IVM 4 months later [41, 44, 47]. 
This first study [47] showed that Wolbachia depletion is antiparasitic (in 
this case, sterilizing female worms) in human filariasis (Figure 7). 
Depletion of Wolbachia by doxycycline was also demonstrated in human 
LF patients infected with W. bancrofti [42, 43, 49, 50]. 
The mode of action of doxycycline, which belongs to the tetracyclines, is 
inhibition of protein biosynthesis by blocking the binding of the 16S part of 
the 30S ribosomal subunit. This prevents the amino-acyl tRNA from 
binding to the A site of the ribosome, and thereby inhibits translation of 
mRNA to protein and finally growth of the cells. 
 
 
            Pictures © by D. W. Büttner 
Figure 7 Doxycycline treatment and Wolbachia depletion 
A= untreated        
B=Doxycycline treated 6 weeks 100 mg/day 
 
Results of this thesis show trials with doxycycline in different dosages and 
treatment times, as well as trials with other antibiotics (rifampicin and 
azithromycin) targeting the Wolbachia endosymbionts in onchocerciasis 
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and LF. Treatment of bancroftian filariasis with a doxycycline 4-, 6- or 8-
week treatment with a 200 mg dose resulted in long-term sterility and 
eventual death of adult worms [42, 43, 49]. The anti-wolbachial therapy 
showed substantial improvements in lymphatic pathology with decreased 
severty in LE and hydrocele in infected individuals [43, 51]. In 
onchocerciasis, a 6-week treatment with 100 mg/day doxycycline resulted 
in long-term (>24 months) sterilization of female worms and absence of 
skin Mf [41, 44, 47]. The slow drug action on adult worm populations of 
doxycycline and activity against Mf give a good safety profile of this 
antibiotc and avoids inflammatory adverse reactions due to Wolbachia 
endobacteria. Considering the long duration of 6-week treatment and the 
fact that young children must not be treated with doxycycline, other 
antibiotics also have to be analyzed for different activities against the 
worms and their endobacteria. Azithromycin showed a good activity 
against intracellular bacteria such as Chlamydia spp. and Mycoplasma spp. 
[52] which are related to Wolbachia. It prevents bacteria from growing by 
interfering with their protein synthesis when it binds to the 50S subunit of 
the bacterial ribosome, and thus inhibits translation of mRNA. Nucleic acid 
synthesis is not affected. It is a safe drug that can be given to children. 
This also applies to Rifampicin, which has already shown good activity  
against Wolbachia in experimental trials [53, 54]. Rifampicin inhibits the 
DNA-dependent RNA polymerase in bacterial cells by binding its beta-
subunit, thus preventing the transcription to RNA and subsequently 
translation to proteins. 
 
1.5 Diagnosis of onchocerciasis and lymphatic filariasis 
Diagnosis of filarial infection is required to determine individuals who need 
treatment, or, with mass treatment programs, where treatment should be 
delivered. It is also important to ascertain the impact an intervention is 
having on the infection and whether or not there is reappearance of the 
infection or renewed transmission in a given area. Moreover, diagnostics 
for filarial infections are important for validating model predictions, and in 
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the future for helping to determine when and where mass-treatment 
activities can be stopped. 
First steps always involve the clinical symptoms; in onchocerciasis, these 
are skin pathology (acute or chronic palpular dermatitis, skin atrophy, 
lichenification and leopard skin), ocular pathology and the presence of 
subcutaneous onchocercomas, mainly around the hips, but also at the 
median side of knees, on the thorax, at the rima ani and on the head. In 
LF, it is mainly signs of lymphatic pathology, such as lymphangitis (filarial 
fewer), lymphedema and pains in the scrotal area due to disturbance in 
the local lymph flow [26].  
Current methods of determining prevalence and intensity of 
onchocerciasis involve palpating nodules of individuals in suspected 
endemic areas and counting of Mf from skin biopsies. Both methods 
involve patient material to identify the worms. This is time consuming and 
requires medical training. Added to that is that a skin biopsy for 
onchocerciasis can be very painful. 
In LF, blood is used for microscopic examination of Mf. This method is 
very specific but insensitive when Mf counts are low or absent, and so it is 
inadequate for detecting early, low-intensity (e.g. after MDA) or pre-
patent infections.  
In bancroftian filariasis, circulating filarial antigen (CFA), which is secreted 
by adult worms before microfilaremia, can be determined from plasma 
through a rapid card test or enzyme-linked immunosorbent assay (ELISA) 
[55, 56]. It has revealed that approximately twice as many individuals are 
CFA positive compared with being microfilaremic, so that a proportion 
equal to the MF positives harbours cryptic infections. Visualizing adult 
worms by USG is also possible in W. bancrofti infections [8]. In brugian 
LF, however, neither the CFA nor the USG methods [9] are able to detect 
cryptic infections, although statistically they must exist. The only way to 
further estimate exposure to brugian parasites is with brugian specific 
IgG4 serology, which can be used as a screening test for filarial exposure, 
since strong and filarial-specific antibody responses are induced upon 
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infection. Several recombinant B. malayi antigens have been used in 
ELISAs or rapid-format assays (Brugia RapidTM)[57] (CELISA)[58] to 
detect filarial specific immunoglobulin IgG4 antibodies. Anti-filarial IgG4 
levels have been demonstrated to be elevated in active filarial infection 
[59-62] and decline post-treatment [63-66]. The advantage of an 
antibody assay is the low cost of the test, high sensitivity (95% in Mf 
positive samples) and availability for B. malayi. However, the anti-filarial 
IgG4 assay has limited use in cross-sectional surveys since it cannot 
discriminate between active infection and past exposure.  
Improved diagnostic methods detecting pre-patent and latent LF infections 
are required. A method of monitoring onchocerciasis and LF before, during 
and after anti-filarial administration that does not rely on skin biopsies or 
night-blood collections would be an improvement in time and labour costs, 
as well as compliance of the study volunteers. 
In the last few years, PCR based assays have become the preferred 
methods for the diagnosis of many parasitic infections in diagnostic 
laboratories for several reasons. First, these assays do not require 
intensive training, experience, or skill in microscopy. Second, the 
equipment and practical skills required to perform PCR are now 
widespread even in the developing world. In recent years, real-time PCR 
has increasingly replaced conventional PCR (C-PCR) for technical reasons 
(improved sensitivity) and practical reasons (faster results). In addition, 
real-time PCR assays have the potential to be used as high-throughput 
diagnostic tools for the screening of DNA extracted from blood and tissue, 
for epidemiological studies, or the monitoring of control programs [67-
69]. 
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1.6 Real-time PCR 
Quantitative real-time PCR (qPCR) is a powerful system for detection and 
quantification of pathogens. Using this system the amount of a given 
pathogen can be precisely estimated, allowing comparison of the pathogen 
load in different samples. Real-time PCR is a highly sensitive technique 
enabling amplification and quantification of a specific nucleic acid 
sequence with detection of the PCR product in real time. In an optimized 
reaction, the target quantity will approximately double during each 
amplification cycle. In quantitative PCR, the amount of amplified product 
is linked to fluorescence intensity using a fluorescent reporter molecule. 
The fluorescence at each cycle of the amplification progress is measured. 
The fluorescence intensity increases proportionally with each amplification 
cycle in response to the increased amplicon concentration. Quantification 
of DNA, cDNA or RNA targets can easily be achieved by determining the 
cycle when the PCR product can first be detected.  
 
 
 
Figure 8 Amplification of standard plasmid dilution series 
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This is in contrast to end-point detection in conventional PCR, which does 
not enable accurate quantification of nucleic acids. In real-time PCR, the 
generation of the amplification products is monitored cycle-by-cycle 
(Figure 8). This allows measurement of the exponential phase of the 
reaction and to fix a threshold cycle (Ct). The threshold cycle is the 
amplification cycle in which the amplification signal passes the threshold 
line (Figure 9). Fluorescence is measured during each cycle, which greatly 
increases the dynamic range of the reaction, since the amount of 
fluorescence is proportional to the amount of PCR product.  
 
 
 
 
Figure 9 Threshold set in the exponential phase 
 
PCR products can be detected using either fluorescent dyes that bind to 
double-stranded DNA (SYBR® Green) or fluorescently labelled sequence-
specific probes (TaqMan®, Molecular Beacons, Scorpions, FRET, MGB) 
(Figure 10). 
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Figure 10 SYBR® Green (A) and TaqMan® (B) principle 
          www.qiagen.com 
 
 
When using SYBR® Green, a melt curve analysis must follow the 
amplification reaction to exclude false positive samples (Figure 11). 
 
 
 
Figure 11 Melt curve analysis in a SYBR® Green real-time PCR assay 
 
Quantification is usually done using a plasmid dilution series as a standard 
curve with a known copy number of the target sequence in each dilution. 
A B 
False 
positive 
PCR 
products 
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A standard curve (plot of Ct values/crossing points of different standard 
dilutions against log of amount of standard) is generated using a dilution 
series of at least 5 different concentrations of the standard (Figure 9). The 
amount of the unknown target sequence should fall within the range 
tested. The Ct value of the unknown sample DNA is compared with the 
standard curve to determine the amount of the target sequence in the 
unknown sample. For more accurate quantification of difficult samples, 
where efficiencies are not always the same as the plasmid reference used 
(<100%), a modified formula of the comparative quantification can be 
used, which is described in more detail in the patients, materials and 
methods section (2.1.8). 
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1.7 Genetic associations in filariasis 
 
The nematodes of bancroftian and brugian filariasis cause lymphatic 
filariasis that shows a spectrum of clinical states with two major poles. 
One pole is represented by microfilaremic patients with high parasite 
numbers and down-regulated cell-mediated responses (asymptomatic), 
and the other pole by symptomatic patients with LE, tropical eosinophilia  
or hydrocele, who typically have few or no parasites, but vigorous specific 
immune reactions [10]. The pathologies develop progressively. It has 
been known that in areas endemic for LF, not all patients that show 
exposure to worms become microfilaremic [70] and that infection status 
(i.e. presence or absence of adult worms) and not the Mf status 
determines cellular responses, although the Mf stage probably contributes 
to a lowered immune response. The actual causes of heterogeneity in 
infection and disease are not well understood, but have been attributed to 
differences in inflammatory processes that are immune-mediated, to 
secondary bacterial infections and to host immunogenetics [71-75]. 
In animal models, Th2 responses, in particular those dependent on 
interleukin (IL)-4, have been shown to limit the occurrence and the extent 
of microfilaremia. Using filarial animal models, it has been shown that 
genetic factors are also involved in the susceptibility to infection in 
different mouse strains [76, 77]. Studies in humans have shown that 
susceptibility to infection, parasite load and lymphatic pathology cluster in 
families independent of household and environment [78-82]. In 
Indonesia, Mf levels have been demonstrated to cluster in families even 
though rates of exposure are equal [81, 82]. An association of the variant 
Arg110Gln in IL-13, thought to lead to higher IL-13 bioactivity, with 
severe skin pathology in onchocerciasis infection has been previously 
shown and is one of the first descriptions of a specific genetic basis for the 
variation seen in filarial pathology [83]. In LF, previous studies have 
shown the association between polymorphisms in various host genes 
[e.g., human leucocyte antigen (HLA), Chitotriosidase (CHIT1), mannose-
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binding lectin (MBL), vascular endothelial growth factor A (VEGF-A) and 
Toll-like receptor 2 (TLR2)] and susceptibility as well as clinical types of LF 
[84-90]. Additionally, a variant in the transforming growth factor-beta 1 
(TGF-β-1) gene in LF patients was found to be associated with the lack of 
Mf and differential Mf loads in blood [91]. 
Results of this thesis show an association of pathology in LF and SNPs in 
the interleukin-18 (IL-18) and the interleukin-4 receptor gene (IL-4R) in 
an Indonesian population infected with B. timori. 
 
IL-18 is a pro-inflammatory cytokine that stimulates both Th1 and Th2 
responses, depending on the cytokine environment (Figure 12) [92].  
Together with IL-12, its primary function is the induction of Interferon- 
gamma (IFN-γ) and tumor necrosis factor-alpha (TNFα) in T-cells and 
natural killer (NK) cells and therefore up-regulation of Th1 cytokines. It is 
expressed by many different cells including macrophages, dendritic cells, 
keratinocytes and osteoblasts [93]. In the absence of IL-12, IL-18 can 
also induce the production of Th2 cytokines by T-cells, mast cells and 
basophiles [94, 95]. In humans, up-regulation of IL-18 production was 
shown in Crohn’s disease [96] and rheumatoid arthritis [97]. The 
expulsion of gastrointestinal nematodes such as Strongyloides 
venezuelensis depends on Th2 responses, and the protective role of IL-18 
in the S. venezuelensis mouse model indicates that IL-18 exerts its 
function against helminth infection through activation of T-cells, 
basophiles and mast cells to produce IL-4, IL-9 and IL-13 [98]. Another 
study analyzing the antigen-specific cellular responsiveness in patients 
exposed to O. volvulus and Entamoeba histolytica infection showed the 
importance of IL-18 in nematode infections [99]. IL-18 reduced parasite-
antigen driven IL-10 secretion by peripheral blood mononuclear cells 
(PBMCs) in individuals exposed to O.volvulus and E.histolytica, whereas 
neutralization of IL-18 clearly enhanced IL-10 release. Chronic pathology 
in LF is associated with a pro-inflammatory response with elevated IFN-γ 
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levels [72-74] and decreased IL-10 levels compared to microfilaremic 
patients [73, 100]. 
 
 
 
Figure 12 IL-18 
IL-18 stimulates both Th1 and Th2 responses, depending on the cytokine environment. The 
combination of IL-18 and IL-12 strongly stimulates various types of cells to produce IFN-γ, which, 
in turn, activates macrophages to produce nitric oxide, leading to the eradication of intracellular 
pathogens such as Leishmania major. However, without IL-12, IL-18 promotes production of Th2 
cytokines by T-cells, basophils and mast cells. Thus, IL-18 can regulate both Th1 (pink box) and 
Th2 (yellow box) responses. Abbreviations: Ag, antigen; DC, dendritic cell; MΦ, macrophage; NKT, 
natural killer T-cell. 
 
Giedraitis et al. first reported that IL-18 promoter gene polymorphisms 
influenced the expression of IL-18 mRNA and potentially also IFN-γ 
expression after stimulation with PMA/ionomycin [101]. As part of this 
thesis we analyzed two SNPs in the IL-18 promoter in patients infected 
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with B. timori from Alor Island, Indonesia. B. timori shares a high degree 
of sequence homology with B. malayi and LE is the most severe pathology 
seen with this infection. We found an association of LE pathology with the 
-607 (rs1946518) and -137 (rs187238) promoter SNPs of the IL-18 gene 
(GeneID: 3606) responsible for elevated IL-18 levels. These SNPs have 
previously been associated with inflammatory diseases such as Systemic 
Lupus Erythematosus (SLE) [102] and sarcoidosis [103].  
 
Additionally two SNPs in the IL-4R gene were found to be associated with 
LF. The IL-4R (GeneID: 3566) is a type 1 transmembrane protein that 
binds the TH2 cytokines IL-4 and IL-13. Both cytokines play key roles in 
the development of TH2 cells, a hallmark of many worm infections. Both 
cytokines use the same receptor alpha chain and seem to share many 
physiological functions. One of their functions is the activation of B-cells 
and induction of proliferation and differentiation of the IgG1 and IgE 
subtypes. Because of their specific signalling pathways they are attractive 
targets for allergy and asthma treatment [104]. The importance of IL-4 
for the control of Mf in murine infection with the filarial nematode 
Litomosoides sigmodontis has previously been described [105, 106]. IL-4 
binds with high affinity to the IL-4R, leading to dimerization with a gamma 
chain to form a type I receptor, or dimerization with the IL-13 receptor 
alpha-1 chain to form a type II receptor (Figure 13). The intracellular 
signal via STAT6 activates IL-4 and IL-13 regulated genes [107, 108]. It 
has been proposed that subtle differences in IL-4 and IL-13 signalling due 
to polymorphisms near docking sites in the IL-4R gene may have profound 
implications for allergy and asthma [104]. 
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Figure 13 IL-4R          http://bionmr-c1.unl.edu/IL13/IL13.htm 
The IL-4 gene encodes the alpha chain of the IL-4 receptor, a type I transmembrane protein that 
can bind IL-4 and IL-13 to regulate IgE antibody production in B-cells. Among T-cells, the encoded 
protein also can bind IL-4 to promote differentiation of Th2 cells. 
 
The Ile50Val SNP (rs 1805010) in the IL-4R gene on chromosome 16 
leads to a change from isoleucine to valine at amino acid position 50 and 
is associated with atopy, asthma and elevated total serum IgE levels 
[109-111]. Previous studies in mouse and human B-cell lines have shown 
a significant association of the Ile 50 form with a 3X greater cell growth 
and luciferase activation (expression under control of the IgE promoter) in 
response to IL-4 compared with Val 50 transfected cells [111]. 
Additionally, in human B-cell lines, increased STAT6 activation in cells with 
the Ile 50 form was observed [111]. These data suggested that the Ile 50 
variant significantly up-regulates receptor response to IL-4. 
The second IL-4R SNP analyzed in our study is in the 3`UTR region of the 
IL-4R gene at mRNA position +3111 (rs 1049631). It has been postulated 
that this SNP is a marker for asthma and atopy [112].  
Knowledge of genomic loci linked to pathology would help in 
understanding pathogenesis which could lead to development of 
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strategies, beside supportive care, to ameliorate pathology in the 40 
million people affected by LE and hydrocele. Knowing genetic markers for 
LE or hydrocele could provide a way to identify persons at risk before 
pathology is seen and might become the basis for development of a rapid 
screening test. 
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1.8 Aims and objectives 
 
1. The first part of this thesis was the establishment of a DNA extraction 
method and quantification of the Wolbachia ftsZ gene in patients treated 
with doxycycline, rifampicin or azithromycin. The PCR results were used to 
support histological results of patients infected with O. volvulus or W. 
bancrofti and confirm a depletion of Wolbachia endobacteria after 
antibiotic treatment.  
 
2. The effect of doxycycline treatment on O. volvulus larvae was analyzed. 
The question was, if Mf of doxycycline treated individuals were able to 
develop in the Simulium vector without their Wolbachia endosymbionts. 
 
3. A PCR for B. malayi infected patients was developed detecting the 
Brugia HhaI gene to establish a detection method for Mf negative patients, 
who may have a pre-patent or latent infection. 
 
4. To get more knowledge of the two poles of pathology in LF, a genetic 
association study of several markers was done to see if there are 
genotypes which could influence the outcome of pathology in LF. 
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2. Patients, materials and methods 
 
2.1 Treatment of 4 and 6 weeks doxycycline in 
onchocerciasis  
 
2.1.1 Study site 
 
In the central region of Ghana, the area south of the river Offin and west 
of the Pra river is endemic for onchocerciasis but not for other human 
filarial infections. Both rivers are breeding sites of the vector blackflies 
Simulium sanctipauli that have flight ranges of up to 12 km [113]. The 
study participants were recruited in three neighbouring villages in the 
Assin district. In 1999, the focus was found to be hyperendemic during a 
rapid assessment of 30 men aged more than 19 years in each village: 75, 
86 and 93% nodule carriers and 80, 89 and 90% Mf carriers were found 
(R.Horstmann, Bernard Nocht Institute, personal communication). Mass 
treatment with IVM started in 1999 in the district. This focus lies south of 
the area of the Onchocerciasis Control Program (OCP) and transmission is 
ongoing. Due to remoteness of the villages, the coverage of IVM was 
rather low until the end of our study in 2005 [113]. During another 
assessment of transmission in 2006 the Simulium infectivity parameters 
closely resembled those from other hyperendemic areas without 
intervention. The entomologists concluded that a person might easily 
receive one or several infective bites per week (R.Garms, Bernard Nocht 
Institute, unpublished report). The nodule loads found during recruitment 
for this study in September 2003 also indicated a high endemicity. 
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2.1.2 Ethical aspects and study design 
 
The study was designed as a randomized, placebo-controlled, double-blind 
study and was approved by the Committee on Human Research and Ethics 
of the school of Medical Sciences of the Kumasi University of Science and 
Technology (KNUST), Kumasi, Ghana, as well as by the Research Ethics 
Committee of the Liverpool School of Tropical Medicine. The study 
conformed to the principles of the Helsinki Declaration of 1964 (last 
amended 2008). 
 
2.1.3 Informed consent, recruitment and examination of the patients 
  
All participants were asked to sign an Informed Consent Form after 
explaining the study in English and in the local language Twi. Individuals 
eligible for participation were: nodule carriers of both sexes, aged 18-62 
years, with a body weight of more than 40 kg, in good health, and without 
any clinical condition requiring chronic medication. Physical examinations 
included inspection and palpation of onchocercomas. The Mf density was 
assessed by two skin biopsies as described previously [114]. Before 
doxycycline respectively placebo treatment and again 3 weeks after 
treatment onset, hepatic and renal functions as well as pregnancy were 
assessed by dip-stick chemistry using venous blood. Exclusion criteria 
were: palpation of less than two onchocercomas, abnormal hepatic and 
renal enzymes and creatinine, pregnancy, breast-feeding, intolerance to 
doxycycline, and alcohol or drug abuse. 
 
2.1.4 Interventions 
 
Patients were treated in September 2003 until October 2003 (Figure 14). 
There were three treatment arms: (1) 6 weeks 200 mg/day doxycycline; 
(2) 4 weeks 200 mg/day doxycycline, followed by 2 weeks matching 
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placebo; (3) 6 weeks matching placebo. Participants received two 100 mg 
capsules of Vibramycin® or matching placebo supplied by Pfizer. There 
was a daily monitoring in the villages of adverse side effects. After 6 
months, a limited number of nodules were excised from some patients of 
the 6-week doxycycline and the placebo groups harbouring many 
onchocercomas, in order to confirm the depletion of Wolbachia. Six 
months after the start of the study and after the first round of 
nodulectomy, the patients received 0.15 mg/kg IVM to deplete skin Mf. 
Based on the results of previous studies [114], patients were 
nodulectomised 20 and/or 27 months after the start of the study in May 
2005 and November 2005. For the nodulectomies patients were admitted 
to the district hospital in Dunkwa. The nodules were excised aseptically 
under local anaesthesia as previously described [41, 115]. 
The study patients had been asked not to participate in IVM mass 
treatment between September 2003 and November 2005. However, they 
were treated with IVM in November 2005-2006 as part of our study 
protocol. 
 
2.1.5 Objectives 
 
The study had two objectives:  
(1) To study in a placebo-controlled manner the efficacy of 4- and 6-week 
treatment with doxycycline followed by IVM, in order to define the 
minimum regimen needed to achieve Wolbachia depletion and complete 
sterilization of adult female worms, leading to a reduction in skin Mf over 
a long period. 2- and 3-week treatment was not sufficient in previous 
studies (unpublished data). 
(2) To assess a potential macrofilaricidal activity of doxycycline on O. 
volvulus.  
Part of my diploma thesis (2005) and this PhD thesis was the 
establishment of real-time PCR assays for quantification of Wolbachia in 
nodule and skin samples of the participants from this study. 
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Figure 14 Patient Flow Chart              (Published by Hoerauf et al., 2008) 
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2.1.6 Nodule and skin preservation 
 
Nodules were prepared for histology and PCR and separated in small 
nodules or more than half of medium or large nodules. Definitions for 
―medium‖ and ―large‖ were diameters of 5-10 mm and more than 10 mm, 
respectively. For PCR analysis the minor portions of the nodules were kept 
at 4°C overnight and then frozen until further processing. Skin biopsies of 
1-3 mg were taken during the nodulectomies from skin tissue near the 
nodule. Biopsies were stored in 80% ethanol until further DNA extraction. 
 
2.1.7 DNA extraction 
 
DNA was extracted using Trizol reagent following the manufacturer’s 
protocol (Invitrogen, Karlsruhe, Germany) by homogenizing 4x30 sec at 
6800 rpm in a Precellys 24 (PeqLab, Erlangen, Germany) using 2.8 mm 
steel beads. DNA was dissolved in 0.8 mM NaOH, pH adjusted to 7.4 with 
1M HEPES (Invitrogen) and further purified using the QIAamp DNA Mini 
Kit (Qiagen, Hilden, Germany) following the protocol for crude cell lysates.  
 
2.1.8 PCR 
 
For the analysis of the extent of Wolbachia depletion by quantitative PCR, 
only nodule and skin samples positive for worm β-actin were included in 
the analysis. The O.volvulus β-actin gene (M84916) was quantified from 
the purified DNA by real-time PCR with the following conditions: 1X 
HotStar® Taq Polymerase buffer (Qiagen), 200 µm dNTP, 300 nM each of 
forward and reverse primer (Appendix I), 0,2 µl SYBR® Green (1:1000 
diluted in DMSO, Roche, Manheim, Germany), 2.5 units HotStar® Taq, and 
2 µl DNA in a 20 µl reaction. The gene was amplified in a Rotor Gene 3000 
(Corbett Research, Sydney, Australia) using the following conditions: 1x15 
min at 95°C, 35 cycles of 94°C for 15 sec, 52°C for 15 sec, 72°C for 15 
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sec. Fluorescence was acquired on the FAM channel. To exclude unspecific 
SYBR® Green products, a melting curve from 62°C-99°C was performed 
after each run. To quantify the amount of O. volvulus Wolbachia ftsZ 
(AJ276501) the same PCR set up was used, except using 200 nM each of 
forward and reverse primer (Appendix I). The profile for the ftsZ gene 
used same conditions as the β-actin PCR, but annealing temperature was 
55°C for 30 sec. 
Copy numbers of each gene were calculated using a modification of the 
comparative quantification formula as described previously [116]. Using 
the Rotorgene 6000 version 6.0 software the amplification (A) of each 
sample was calculated and the mean taken from the replicate samples 
(sam). A plasmid containing either the ftsZ or the β-actin sequence was 
quantified and copies/µl determined for use as a reference (ref) in each 
PCR run. The amplification factor of the sample compared to the specific 
reference was then calculated using the following formula: 
Aref ^ take offref / Asam ^ take offsam  
The take off is defined as the crossing point cycle where all measured 
samples are 20% above background. The amplification factor was 
multiplied by the known concentration of the reference to give copies/µl 
and the ftsZ/actin ratio was calculated. 
Particularly in the skin samples of African decent, it was previously found 
that inhibition of the PCR reaction can occurre due to melanin 
contamination [117, 118]. Therefore an inhibition test with a reference 
plasmid (murine IFN-γ) was done. The samples were set up for real-time 
PCR with a mastermix containing 1X HotStar® Taq Polymerase buffer 
(Qiagen), 200 µm dNTP, 400 nM each of forward and reverse primer 
(Appendix I), 0,2 µl SYBR® Green (1:1000 diluted in DMSO, Roche, 
Manheim, Germany), 2.5 units HotStar® Taq, and 2 µl reference plasmid 
DNA and 2 µl samples DNA in a 20 µl reaction. The PCR profile was: 1x15 
min at 95°C, 45 cycles of 94°C for 15 sec, 58°C for 20 sec, 72°C for 20 
sec. Fluorescence was acquired on the FAM channel. 
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Samples were considered uninhibited when the reactions with sample DNA 
were detected at the same level as the reference plasmid control sample. 
 
2.1.9 Statistics 
 
Differences in ftsZ/β-actin ratios between doxycycline and placebo treated 
patients were analyzed using the Mann-Whitney-U Test with the GraphPad 
Prism Software, version 5.01 (GraphPad Software, La Jolla, CA, USA). P 
values ≤0.05 were considered significant. 
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2.2 Treatment of 5 weeks doxycycline in onchocerciasis 
 
2.2.1 Study site 
This open trial was conducted between August 2003 and November 2006 
in the Assin district, Central Region of Ghana (detailed description in 
2.1.1). 
 
2.2.2 Ethical aspects, informed consent and inclusion criteria 
As described in 2.1.2 and 2.1.3. 
 
2.2.3 Patient treatment and nodulectomies 
 
Twenty-four volunteers were included in the study (Figure 15). They 
received 100 mg capsules of doxycycline daily for 5 weeks (Vibramycin®, 
supplied by Pfizer, Karlsruhe, Germany). Doxycycline was administered 
after patients had taken a meal and the treatment was monitored daily by 
a physician. Two individuals did not complete the treatment. All 
participants were requested not to take part in IVM mass treatment during 
the study. They received IVM as part of our study after the nodulectomies 
at 27 months (11/2005) and after re-examination at 39 months 
(11/2006). 
At 21 and 27 months after the beginning of doxycycline treatment, 
nodulectomies were performed aseptically under local anaesthesia in the 
Dunkwa Regional Hospital, as described [115].  
 
 
 37 
 
 
 
 
In addition to the doxycycline-treated patients, ten patients from the 
same village, who had not been enrolled in the study and had received 
neither doxycycline nor IVM, were enrolled for nodulectomy at 21 and 27 
months as controls.  
 
2.2.4 Objectives and Outcome measurements 
 
Previously we had studied the efficacy of 100 or 200 mg/day doxycycline 
administered for 6 weeks [41, 47]. The aim of this study was to 
investigate the effects of a shortened regimen of only 5 weeks doxycycline 
 Figure 15 Patient Flow Chart 
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treatment on the depletion of Wolbachia endobacteria from O. volvulus, 
on interruption of embryogenesis and Mf production, and to detect 
macrofilaricidal activity. 
The primary outcome measurements were female worm fertility, adult 
worm survival, and the presence of Wolbachia endobacteria. All 
parameters were assessed by immunohistology of extirpated nodules. 
Presence of Wolbachia was additionally assessed by quantification of the 
bacterial ftsZ gene normalized to the worm β-actin gene (part of this 
thesis). 
The secondary measurement was the analysis of skin Mf from two skin 
biopsies that were taken from the doxycycline-treated and untreated 
control patients at study onset as well as at 21 and/or 27 months later. 
 
2.2.5 Nodule and skin preservation 
 
Immediately after extirpation, the nodules and skin samples were fixed in 
80% ethanol or in buffered 4% formaldehyde solution for 
immunohistology. 
Further preparation of nodule and skin tissue was as described in 2.1.6. 
 
2.2.6 DNA extraction 
 
DNA was prepared as described in 2.1.7. 
 
2.2.7 PCR 
 
PCR was performed for Wolbachia ftsZ and worm β-actin as described in  
2.1.8. Same primers and PCR profiles were used. 
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2.2.8 Statistics 
 
Differences in ftsZ/β-actin ratios between doxycycline and placebo treated 
patients were analyzed using the Mann-Whitney U Test as discribed in 
2.1.9. Treatment of 6 weeks azithromycin in onchocerciasis 
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2.3 Treatment of 6 weeks azithromycin in onchocerciasis 
 
2.3.1 Study site, ethical aspects and study design 
 
This open trial was conducted in the Upper Denkyira district in the Central 
region of Ghana from 2002-2003. In 1999, a rapid assessment of 30 men 
older than 19 years in each village had identified many hyperendemic foci 
in the district (R.Horstmann and D.W. Büttner, Bernard Nocht Institute). 
Three villages were selected 2-9 km south of the river Offin, where 
Simulium sanctipauli vectors breed [113]. IVM mass treatment had 
started in Denkyira in 1999, but not all villages had been included until 
2003 and not all eligible villagers had participated. 
The study was approved by the Ethical Research Committee of the School 
of Medical Science of the Kwame Nkrumah University of Science and 
Technology, Kumasi, Ghana. It conformed to the principles of the Helsinki 
Declaration of 1964 (last amended 2008). Informed consent was obtained 
from each participant. 
Individuals eligible for treatment were adult men aged 18-60 years. In 
order to respond to the request by the villagers that women could also be 
part of the study, women were included as untreated controls for later 
nodulectomy. Further inclusion criteria were as described in 2.1.3. Here, 
exclusion criteria additionally encompassed a history of intolerance to 
azithromycin or erythromycin. 
 
2.3.2 Treatment and nodulectomy 
 
In the Praprababida community, 26 patients were recruited in January 
2002 (Figure 16). Twenty-three patients were treated 6 weeks with 250 
mg/day azithromycin (Zithromax® 250-mg tablets, Pfizer, Karlsruhe, 
Germany). In the Asma Camp community, 18 patients were recruited and 
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14 of them completed treatment with 1,200 mg azithromycin once per 
week for 6 weeks (two Ultreon® tablets, Pfizer). 
At 6 or/and 12 months after the onset of treatment, nodulectomies were 
performed aseptically under local anaesthesia as described in 2.1.4. 
In addition to the azithromycin-treated patients, nine untreated 
onchocerciasis patients from the Ayebiahwe community were 
nodulectomised at 12 months. All participants were administered IVM 
after the nodulelectomies at 12 months. 
 
 
Figure 16 Patient Flow Chart  (Published by Hoerauf et al., 2008) 
 
2.3.3 Objectives and Outcome measurements 
 
The aim of the study was to analyse the effects of azithromycin on the 
presence of Wolbachia endobacteria and on embryogenesis and Mf 
production of O.volvulus. The primary outcome measurements were 
presence of Wolbachia and female worm fertility assessed by 
immunohistology of extirpated nodules as published by Hoerauf et al. in 
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2008 [119]. To expand and support histological results, presence of 
Wolbachia in extracted DNA of nodule tissue and quantification by real-
time PCR was done as part of this thesis. 
2.3.4 DNA extraction and PCR 
 
DNA of nodules was extracted as described in 2.1.7. PCR conditions for 
the Wolbachia ftsZ gene and the β-actin gene of O. volvulus were the 
same as in 2.1.8, except the DNA was diluted 1:100 prior the PCR run due 
to a high amount of DNA after extraction. 
 
2.3.5 Statistics 
 
Differences in ftsZ/β-actin ratios between azithromycin treated or 
untreated patients were analyzed using the Mann-Whitney U Test as 
discribed in 2.1.9. 
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2.4 Treatment with rifampicin and/or doxycycline in 
bancroftian filariasis 
 
2.4.1 Study site, ethical aspects and study design 
 
This randomized open trial was conducted in the coastal villages of 
Asanta, Sanwoma, Agyambra and Miamia in the Nzema East and the 
Ahanta West District in the Western Region of Ghana from 2005-2008. 
The study site was selected based on an established occurrence of W. 
bancrofti infection within the surrounding region and clinical observations 
consistent with symptomatic disease in the villagers [43, 120]. Written 
informed consent was obtained from all participants and the study was 
approved by the Ethical and Research Committee of the School of Medical 
Sciences of the Kwame Nkrumah University of Science and Technology, 
Kumasi, Ghana. The study conformed to the principles of the Helsinki 
Declaration of 1964 (last amended 2008).  
Individuals eligible for participation were adult men aged 18-60 years, 
with a minimum body weight of 40 kg, in good health without any clinical 
condition requiring chronic medication.  Exclusion criteria encompassed a 
microfilarial load <20 Mf/ml, abnormal hepatic and renal enzymes (above 
AST [0-40 IU/L], ALT [0-45 IU/L], creatinine [53-126 µmol/L]) assessed 
by dipstick chemistry, and alcohol or drug abuse. Leukocyte and 
differential counts of thin blood smears were also done. 
 
2.4.2 Doxycycline and rifampicin treatment 
 
In all, 48 men were recruited for the study and 39 completed the 
treatment course (Figure 17). Nine men dropped out and could not 
complete the treatment because they either moved from the villages or 
could not comply with the daily-observed treatment because of fishing 
activities. Of the 39 men, 12 were treated with 200 mg doxycycline/day 
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for 4 weeks, 16 patients with 200 mg doxycycline/day + 10mg/kg/day 
rifampicin for 2 weeks + 2 weeks placebo matching doxycycline and 11 
patients were treated with placebo matching doxycycline for 4 weeks. Due 
to unavailability of rifampicin placebo at the time, the rifampicin study was 
an open study while for the doxycycline capsules matching placebo were 
available and this part of the trial was placebo-controlled. Four months 
after the start of treatment, all participants received a standard oral dose 
of 400mg ALB (GlaxoSmithKline) and 150 g/kg IVM (Mectizan®, Merck, 
Sharp & Dohme). 
 
Figure 17 Patient Flow Chart (Published by Debrah et al., 2011) 
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2.4.3 Determination of Wolbachia levels in Mf by real-time PCR 
 
One outcome measurement of this study was to quantify Wolbachia ftsZ 
single copy genes per Mf at pre-treatment and 4 months after treatment 
onset. The numbers of Wolbachia/Mf and microfilaremia were determined 
from a 10 ml blood sample taken between 21h and 23h. One ml of the 
blood was filtered through a 5 µm Whatman Nucleopore filter to hold back 
Mf. The filter was stained using the Giemsa method and Mf were counted 
using a microscope [43, 120]. A second filter was used to filter a blood 
volume calculated to have 500-1000 Mf. This filter was stored at –80°C 
until later analysis of Wolbachia gene copies by quantitative PCR. Due to a 
reduced sample number of Mf positive patients at 12, 18 and 24 months 
after treatment, PCR was only done at pre-treatment and 4 months after 
treatment onset. 
 
2.4.4 DNA extraction 
 
DNA was extracted using the QIAamp DNA Mini Kit (Qiagen, Hilden, 
Germany) following the tissue 2a protocol. A calculated number of 500-
1000 Mf trapped on a Whatman filter was digested with proteinase K. 
Instead the recommended short incubation with proteinase K, incubation 
was extended to an overnight incubation at 56°C. 
 
2.4.5 Determination of Wolbachia levels in Mf by quantitative PCR 
 
The Wolbachia in Mf content was quantified by real-time PCR of the W. 
bancrofti Wolbachia ftsZ gene (AF081198) derived from 500-1000 Mf. 
Purified DNA was quantified by real-time PCR on a Rotor Gene 6000 
(Corbett Research, Sydney, Australia). The mastermix contained: 1x 
HotStar® Taq Polymerase buffer (Qiagen), 200 µM dNTP, 4.5mM MgCl2, 
300 nM of forward and 900 nM of reverse primer (Appendix I), 0.1 µl of 
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hybridisation probe (Appendix I), 2.5 U HotStar® Taq Polymerase, and 2 
µl DNA in a 10 µl reaction. The 2-step profile started with a 95°C 
activation step for 15 min, followed by 45 cycles with 95°C for 15 s and 
60°C for 30 s. 
The products were quantified by comparing with a standard curve of the 
plasmid containing the ftsZ fragment. 
To verify the worm content of the individual sample, a second PCR assay 
for W.bancrofti β-actin (AF 184961) was done. 
The mastermix contained 1x HotStar® Taq Polymerase buffer (Qiagen), 
200 µM dNTP, 4 mM MgCl2, 900 nM of forward and reverse primer 
(Appendix I), 0.1 µl of SYBR® Green (1:1000 diluted in DMSO, Roche, 
Mannheim, Germany), 2.5 U HotStar® Taq Polymerase, and 2 µl DNA in a 
10 µl reaction.  
The PCR profile contained a 15 min initiation with 95°C, followed by 40 
cycles of 95°C 10s, 58°C 30s and final extension at 72°C for 20s. Melt 
curve analysis showed a specific peak at 80°C for all positive samples. 
For the analysis of the extent of Wolbachia depletion by quantitative PCR, 
only samples which were positive for worm β-actin were included in the 
analysis. 
 
2.4.6 Statistics 
 
Depletion of Wolbachia loads from Mf by doxycycline alone and 
doxycycline+rifampicin, and comparison of microfilaremia between various 
treated groups were summarized as medians. Differences in medians at 
baseline and subsequent follow-ups were analyzed using Wilcoxon Signed 
Rank test of raw data. All analyses were done using tests included in the 
PASW® software version 18. 
 
 
 
 47 
2.4.7 Additionally outcome measurements 
 
PCR was only one part of the study. Additionally, determination of 
circulating filarial antigenaemia and ultrasound examinations (USG) for 
filarial dance sign (FDS) were done by Dr. Sabine Mand and Dr. Alex Yaw 
Debrah [121]. 
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2.5 Retarded O. volvulus L1 to L3 larval development in the 
Simulium damnosum vector after anti-wolbachial 
treatment of the human host 
 
2.5.1 Ethical approval 
 
This study received ethical clearance from the Institutional Review Board 
of the Tropical Medicine Research Station, Kumba and was conducted in 
accordance with the Helsinki Declaration of 1964 (last amended 2008). 
 
2.5.2 Selection of study patients and treatment 
 
In November and December 2006, participants for the study were 
recruited in four neighbouring villages in an onchocerciasis-endemic region 
of South West Cameroon. Patients for the study were selected from male 
volunteers, aged between 21 and 50 years after informed consent was 
signed. Exclusion criteria were abnormal hepatic (SGPT and SGOT) and 
renal (creatinine) functions, persons with chronic infections and under 
prolonged medication, alcohol abuse and intolerance to doxycycline. As 
there was mass treatment with IVM in the area in April 2006, all patients 
were asked whether they took their dose at this time or any time before, 
but all volunteers answered in the negative. Inclusion criteria were 
absence of other clinically manifest diseases as assessed by a medical 
doctor and > 10 Mf in skin biopsies. Two bloodless skin biopsies, one from 
each iliac crest of each participant, were aseptically obtained using a Holth 
corneoscleral punch. Each biopsy was immersed in 2 drops of 0.9% NaCl 
solution in a separate well of a labelled 96-well round-bottom microtiter 
plate. 
The plates were transported to the laboratory and skin biopsies were 
incubated overnight at room temperature to allow the emergence of Mf 
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into the saline solution. The Mf were counted using 10-fold magnification 
of a microscope and the numbers of Mf were expressed as Mf per skin 
biopsy. 
Twelve volunteers were blindly allocated into two treatment groups. One 
group of 7 volunteers received doxycycline (200 mg/day) for 6 weeks 
while the second group of 5 volunteers received matching placebo. 
 
2.5.3 Infection of wild Simulium flies with O. volvulus 
 
Before and after treatment, the volunteers were brought to a pre-selected 
capture point near a Simulium breeding site on the bank of the River 
Mungo to allow Simulium damnosum flies, the vector of O. volvulus, to 
take a blood meal. The site was chosen based on the results of dissection 
of wild Simulium flies to determine their natural parous, infection and 
infective rates. These parameters were monitored throughout the study 
period. The fed flies were captured on the volunteers in small plastic 
containers. Containers for each volunteer were kept separately in plastic 
baskets. At least four hundred flies were caught from each patient in four 
days at each time point. Transport to the insectarium was carried out in 
cold boxes. The flies were then kept for 7 days at 25°C and 80% relative 
humidity to allow the Mf to develop into infective third stage larvae (L3). 
Larvae were isolated from the flies by dissection using a dissecting 
microscope and their developmental stages were scored. The number of 
flies dissected at each time point varied due to different fly mortality 
rates. The isolated developmental stages of the L1 (first larval stage), L2 
(second larval stage) and L3 (third, infective larval stage) were stored 
separately in 80% ethanol. At least two tubes each containing different 
numbers of L1, L2 and L3 isolated from flies fed on each volunteer at each 
time point were stored for later DNA extraction and quantification of 
Wolbachia. 
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Figure 18 Time line 
 
2.5.4 Follow-up of volunteers and monitoring of Mf load after treatment 
 
During the following 5 months, flies were captured on a monthly basis on 
the volunteers as described above (Figure 18). Skin biopsies were also 
obtained from the patients at each time point to assess their Mf load after 
the antibiotic treatment. After counting, the Mf were stored in 80% 
ethanol for later quantitative PCR analysis to determine their Wolbachia 
content. 
 
2.5.5 Kinetics of larval development 
 
The total number of L1, L2 and L3 collected after dissection of the flies 
was calculated from doxycycline and placebo treated individuals. The 
proportion of each larval stage generated for that month in each group 
was calculated and plotted against the month of dissection to follow the 
kinetics of the development of larvae in both treatment groups. At pre-
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treatment and one month follow-up, the L1 and L2 larvae counts were 
combined. 
 
2.5.6 DNA extraction from larvae 
 
One tube each of the different stages of larvae (L1, L2 and L3) per time 
point preserved in ethanol was randomly selected for DNA extraction and 
quantification of Wolbachia. The larvae preserved in ethanol were first 
centrifuged at 1800 rpm in a LH 4000 rotor (Multifuge 4KR, Heraeus, 
Haunau, Germany) for five minutes. The ethanol was slowly removed with 
a pipette without disturbing the larvae, leaving 100 µl of volume. These 
larvae were then suspended in the remaining ethanol and transferred to a 
new tube. DNA was extracted using the QIAamp® DNA mini Kit (Qiagen, 
Hilden, Germany) following the tissue protocol of the kit with the following 
modifications to achieve the maximum amount of quality DNA. The 
incubation period with proteinase K (Qiagen) was extended from 10 min 
to overnight at 56°. Wash buffers 1 and 2 were increased to 700 µl 
followed by elution with 2X50 µl of AE buffer. For each elution step, the 
columns were incubated with AE buffer for 5 minutes at room temperature 
prior to centrifugation. 
 
2.5.7 Quantitative real-time PCR 
 
To determine the amount of Wolbachia in the larvae isolated from the 
vector captured after having fed on doxycycline or placebo treated 
individuals, the purified DNA samples of randomly selected larvae for each 
volunteer and time point were analyzed by quantitative real-time PCR. 
Primers were used from previous analysis (2.1-2.3) and a hybridization 
probe was designed with Primer3 software [122] for the O. volvulus 
Wolbachia ftsZ gene (GenBank accession no. AJ276501). For all samples 
the following master mix was used: 1x QuantiTect® Virus NR Master Mix 
 52 
(Qiagen), 300 nM each forward and reverse primers (Appendix I), 50nM 
TaqMan hybridisation probe (Appendix I) (Biomers, Ulm, Germany), 2.5 U 
HotStar® Taq Polymerase and 10 µl of sample DNA in a 20 µl reaction. The 
PCR program utilized a two-step reaction of the following conditions in a 
Rotor Gene 6000 (Corbett Research, Sydney, Australia): 1x 5 min at 
95°C, 45 cycles of 94°C for 10 s and 58°C for 45s. Fluorescence was 
acquired on the FAM channel at 58°C. 
A second PCR was performed which quantified the amount of O.volvulus 
β-actin (GenBank accession no. M84916) to normalize the ftsZ values 
[123] as discribed in 2.1.8. In both PCR assays, each sample was 
analyzed in triplicate. Every run contained a plasmid specific for each gene 
with a known number of copies for use as a standard curve reference. A 
no-template control of water instead of sample DNA was used as negative 
control. Copy numbers for each gene were calculated using a modification 
of the comparative quantification formula as described in 2.1.8.  
To exclude inhibition of the PCR reaction by inhibitors in DNA a third PCR 
with a plasmid containing a fragment of the murine INF-γ was performed 
in the presence of the extracted DNA as discribed in 2.1.8. 
 
2.5.8 Data analysis and statistics used 
 
The proportions of larvae were analyzed by calculating the L3/total larvae 
and L1+L2/total larvae ratios. Statistical significance between larvae of 
vectors fed on doxycycline or placebo treated individuals was determined 
with the Mann-Whitney U test (P ≤0.05 was considered significant) with 
the PASW® 18 software (IBM, Chicago, USA). Results were presented using 
the median with 95% CI. 
Larval recoveries were expressed as median with 10-90th percentiles. 
Wolbachia quantities of the PCR results were expressed as the ratio of 
ftsZ/β-actin. 
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2.6 Detection of HhaI gene in infection with B. malayi by 
real-time PCR 
 
2.6.1 Plasma from B.malayi infected patients from Indonesia 
 
Samples were received from a larger study conducted in Budong-budong 
[124, 125], a district of Mamuju Regency in South-Sulawesi, Indonesia, 
which is endemic for periodic nocturnal B. malayi [126]. A transmigrant 
population had traveled to their new homesteads in groups coming from 
the same village or region in Bali or certain Lesser Sunda islands as part 
of the government-sponsored relocation program between 1990 and 
1996. A total of 6 transmigrant units, settled between several months and 
6 years prior to the survey, were included in the study together with 2 
villages of indigenous Sulawesian villages, which were situated closely to 
the transmigration areas. Transmigrants from areas where filariasis is 
endemic (South Sulawesi and other Lesser Sunda islands) were excluded 
from the analysis. In co-operation with the medical doctors and health 
workers of the local District Health Centre and the head of each 
transmigration unit or village, all residents were informed about the study 
and invited to participate. Informed consent was obtained from all study 
participants or parents of underage children before parasitological studies 
and blood withdrawal in accordance with the guidelines of the Indonesian 
Department of Health and Human Services. The study was approved by 
the ethics committee of the Hasanudin University, Indonesia. A total 
number of 247 transmigrants and 133 life-long residents (LLR) were 
enrolled in the study [125]. 
 
2.6.2 Blood tests (done by Terhell and colleagues) 
 
Venous blood samples of 10 ml were collected between 20:00h-24:00h 
and preserved with EDTA at a final concentration of 0.05 M. The tubes 
 54 
were centrifuged and plasma was stored at -20°C for several months until 
shipment to Europe, where it was stored at -70°C until use. Parasitological 
examination and detection of filarial spesific IgG4 antibodies using a 
soluable worm antigen (SWA) based ELISA and BmR1 dipstick assay 
(Brugia RapidTM) were done as previously described [124, 125]. 
 
2.6.3 DNA extraction and PCR 
 
DNA was extracted from 100 µl plasma with a QIAcube® (Qiagen, Hilden, 
Germany) using the QIAamp® DNA Blood Mini Kit. The recommended 
protocol for blood and body fluid was used and DNA was eluted in 100 µl 
AE-Buffer. 
For the PCR assay, a QuantiTect® custom assay was designed with specific 
primers and a minor groove binding probe (MGB, QuantiProbe®) for 
detection of 120 bp of the HhaI repeat in Brugia species. The HhaI repeat 
(M12691 and AF499109 to AF499129) was used as the target sequence 
for several reasons. This sequence is arranged as a tandem repeat and is 
present in several thousand copies per haploid genome [127]. 
Furthermore, most conventional PCR assays for Brugia have used this 
target, and no consistent sequence variation has been reported in various 
strains of B. malayi and B. timori. The HhaI repeat is AT rich and closely 
related sequence are present in zoonotic filarial species such as B. 
pahangi; this makes it difficult to design primers and probes specific for 
the Brugia species that are parasitic in humans (B.malayi and B. timori). 
In addition, even within one parasite, the numbers of HhaI copies is not 
identical, and there are conserved and more variable areas. Conserved 
regions rarely span more than 30 bp, and selection of long primers and 
probes can decrease detection sensitivity. 
The use of modified nucleotides (―superbases‖) together with a minor 
groove binding probe (MGB) increases the melting temperatures of 
oligonucleotides to complementary sequences.  
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Figure 17 QuantiProbe® Principle QuantiProbes, included in QuantiTect Custom Assays, 
operate as hybridization probes, with Superbases for increased stability.  A  When not bound to its target 
sequence, the QuantiProbe forms a random structure in solution. The proximity of the fluorescent reporter with 
the quencher prevents the reporter from fluorescing.  B  During the PCR annealing step, the QuantiProbe 
hybridizes to its target sequence. This separates the fluorescent dye and quencher, resulting in a fluorescent 
signal. The amount of signal is proportional to the amount of target sequence, and is measured in real-time to 
allow quantification of the amount of target sequence.  C  During the extension step of PCR, the probe is 
displaced from the target sequence, bringing the fluorophore and quencher into closer proximity, resulting in a 
decrease in fluorescence without hydrolysis of the QuantiProbe. This means that the concentration of the 
QuantiProbe remains constant during the PCR, enabling reliable quantification. 
 
 
The primer and probe sequences were obtained from previously published 
results of Rao et al. [128], and were purchased from Qiagen as 20x 
concentrates. The reaction mixture for the real-time PCR consisted of 10 
µl of 2x QuantiTect® Probe PCR Master Mix (containing HotStar® Taq DNA 
Polymerase, QuantiTect® Probe PCR buffer, dNTP mix and 8 mM MgCl2), 1 
µl Primer Mix 20x and 0.5 ml QuantiProbe® solution 20x (Appendix I) in a 
20 µl reaction. Cycling conditions on the RotorGene 6000 (Corbett 
Research, Sydney, Australia) included an initial activation for 15 min with 
95°C and 45 cycles with 15 sec at 94°C, 30 sec at 56°C and extension for  
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30 sec at 76°C. Fluorescence was acquired on the FAM channel during the 
annealing step at 56°C. Target sequence copy numbers were calculated 
from the Ct values by using an external standard curve generated with a 
HhaI plasmid dilution series, which allowed 100% detection in samples 
with >200 copies/µl and 85% in the range between 20 and 200 copies/µl. 
For generating the external standard curve, the higher dilutions were 
measured in triplicates, lowest dilution (2 and 20 copies/µl) were 
measured with 10 replicates in three separate runs. All other PCRs were 
carried out in duplicates. 
Samples containing a very low amount of DNA and without positive HhaI 
detection were measured in a second PCR assay using the QuantiTect® 
Virus NR mastermix (Qiagen). This modified mastermix allows for an 
increased volume of sample DNA in the PCR reaction up to 10 µl and is 
useful for samples with low concentrations of target DNA. The reaction 
mixture contained 4 µl of 5x QuantiTect Virus NR mastermix (containing 
HotStar® Taq Plus DNA Polymerase, QuantiTect® Virus PCR buffer, dNTP 
mix and MgCl2), 1 µl Primer Mix 20x and  0.5 ml QuantiProbe
® solution 
20x (Appendix I) in a 20 µl reaction. The profile on a RotorGene 6000 
included an initial activation for 5 min with 95°C and 45 cycles with 15 sec 
at 94°C and 30 sec at 60°C. Fluorescence was acquired on the FAM 
channel during the annealing step at 60°C. 
To exclude any inhibiting factors in the extracted DNA from plasma, a test 
for inhibition was done as described in 2.1.8. 
To verify the DNA content in each sample, a PCR was done detecting the 
human β-actin gene (Gene ID: 60). The Mastermix contained 1X HotStar® 
Taq Polymerase buffer (Qiagen), 200 µm dNTP, 300 nM each of forward 
and reverse primers (Appendix I), 0,2 µl SYBR® Green (1:1000 diluted in 
DMSO, Roche, Mannheim, Germany), 2.5 units HotStar® Taq Polymerase, 
and 2 µl DNA in a 20 µl reaction. The gene was amplified in a Rotor Gene 
3000 (Corbett Research, Sydney, Australia) using the following conditions: 
1x15 min at 95°C, 35 cycles of 94°C for 15 sec, 58°C for 15 sec and 72°C 
for 15 sec. Fluorescence was acquired on the FAM channel. To exclude 
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unspecific SYBR® Green products, a melting curve from 62°C-99°C was 
performed after each run. 
 
2.6.4 Plasma from B.malayi infected jirds 
 
Jirds (Meriones unguiculatus) were infected with L3 (infective third stage 
larvae) of B. malayi. Eight weeks (56 days) after infection, plasma was 
collected and adult worm recovery was documented. No Mf could be found 
at this time point indicating a pre-patent status of the jirds. The patent 
period of B. malayi infected jirds usually starts between 75 and 110 days 
after infection [129]. DNA was extracted of 100 µl pelleted plasma with 
the QIAamp® DNA Mini Kit. The pellet was dissolved with 180 µl ATL 
buffer and proteinase K for one hour at 56°C. DNA was quantified as 
described in 2.6.3 using the QuantiTect Virus NR mastermix and the 
protocol with 10 µl sample DNA per reaction. 
 
2.6.5 DNA extraction from plasma used as positive/negative controls 
 
To test the specificity of the HhaI PCR assay plasma samples from ten W. 
bancrofti infected individuals, 15 patients with other parasitic infections 
and ten European blood donors without history of a parasitic infection 
were extracted according to the protocol described in 2.6.3. All volunteers 
had signed an informed consent. These samples were used as negative 
controls. Another 30 plasma samples from Mf positive patients and 9 from 
LE patients from Central Sulawesi were extracted as descibed and used as 
positive reference samples. 
 
2.6.6 Determination of a threshold of active infections by PCR 
 
A threshold limit of HhaI copy numbers was determined to differentiate 
most-likely ―active‖ infections from simple exposure to infective larvae. 
For this the Mf loads of Mf positives (Central Sulawesi and South Sulawesi 
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transmigrants, n=49) and LE patients (Central Sulawesi, n=9) were 
correlated to HhaI copies/µl to calculate the Y-intercept from the linear 
regression. The results were further analysed by a Receiver-Operating 
Characteristics (ROC) curve analysis using a binormal mixture model 
[130, 131]. Individual samples were scored positive (Mf positive, LE) or 
negative (transmigrant samples of the ≤ 1 month and 2-4 months group) 
since the L3 to adult worm development requires about 8 months. The 
Area Under the Curve (AUC) for the ROC-curve was calculated to measure 
the discriminatory power of the PCR assay [132]. 
 
2.6.7 Statistical analyses 
 
PASW 18.0 (IBM®, Somers NY, USA) was used to test the comparison of 
two binary variables with the Fisher`s exact test, to correlate between two 
continuous parameters using Spearman`s rank test and ROC-curve 
analysis. The Cochran-Armitage test for trend was calculated with SAS 9.2 
(SAS, Cary, NC, USA) to compare the trend of HhaI copy numbers 
between the 0.1-3 year and the 4-6 years residents. This trend test 
modifies the chi-square test and is used in categorical data analysis when 
the aim is to assess the presence of an association between a variable 
with two categories and a variable with k categories and to incorporate a 
suspected ordering in the effects of these categories. In this study the two 
categories were individuals resident 0.1-3 years and 4-6 years; k = the 
intervals for HhaI copies/µl. P<0.05 was considered significant. 
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2.7 Genetic associations in brugian filariasis analyzed in 
patients from Alor Island, Indonesia 
 
2.7.1 Study population 
 
The participants in this case-control study were from Alor Island, 
Indonesia, who took part in a larger parasitological study of B. timori 
infection [133]. Alor Island is located north of Timor and has 
approximately 164,000 inhabitants. The highland village of Mainang was 
chosen for the detailed study and is located in a swampy valley, an 
excellent breeding site for Anopheles mosquitoes, the vector of B. timori. 
The study was approved by the Indonesian Ministry of Health and the 
University of Indonesia, Jakarta. Samples were collected from March to 
May 2001. The participants of the detailed survey in Mainang originated 
from three different residential areas of the village: Welai Selatan, 
Malaipea and Tominuku. A house-to-house survey was carried out in these 
quarters to determine the eligible population. All individuals having lived 
in the area for more than four years were asked to participate in the 
study. Inhabitants from Welai Selatan and Malaipea came voluntarily to 
the health center. To exclude a bias due to self-selection, all inhabitants of 
Tominuku who were present in the village were asked individually to take 
part in the study. About 90% of the selected persons participated in the 
survey. Other individuals who heard about the survey and asked for an 
examination were examined but excluded from the study population. 
Informed consent was obtained from all persons participating in the 
survey. 
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2.7.2 Phenotyping 
 
After registration, all individuals were examined by experienced physicians 
for clinical signs of lymphatic filariasis, including enlarged or tender 
superficial inguinal and femoral lymph nodes, acute lymphadenitis and 
lymphangitis of the extremities, scars at the sites of previously ruptured 
lymph nodes or vessels, or LE of the extremities. LE of the limbs was 
classified from grade 1 (pitting, reversible LE) to grade 4 (elephantiasis, 
non-pitting edema with fibrotic and varicose skin changes) [134]. All 
participants were additionally asked for a history of clinical signs related to 
lymphatic filariasis. All persons with LE, including those with elephantiasis, 
were asked for a day blood collection on the next morning between 10:00 
A.M. and noon. 
To determine the status of microfilaremia, 1 ml of venous night blood was 
collected and filtered using 5 µm polycarbonate filters (Millipore, 
Eschborn, Germany). Filters were stained with Giemsa solution and 
examined with 100X magnification and the Mf were counted. Filarial-
specific IgG4 antibodies to recombinant BmR1 antigen were assessed as 
described previously [135]. Additional blood was collected and diluted 1:1 
with 8 M urea for later DNA extraction. 
Patients with LE were introduced to hygienic methods to use on their 
affected legs and other procedures that may help stop progression of the 
disease. Following the survey, treatment using a combination of a single 
dose of DEC (6mg/kg of body weight) and of ALB (400 mg) was offered to 
all infected individuals. 
 
2.7.3 Genotyping 
 
In total the association of LF with 30 SNPs was analyzed (Appendix II). 
From the original 586 participants of the parasitological study, we 
identified 122 unrelated cases and controls and genotyped them for IL-18 
SNPs -607 (rs1946518) and -137 (rs187238) and IL-4R SNPs Ile50Val (rs 
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1805010) and +3111 3’UTR (rs1049631). Individuals were defined as 
related if the nearest common ancestor made them first-degree relations. 
For the IL-18 SNPs, cases for LE were defined as persons with LE stage 2-
4 [134]. Controls were persons with no lymphatic pathology, but positive 
for IgG4 antibodies to filarial antigen. For the IL-4R SNPs, cases for 
microfilaremia were defined as unrelated persons positive for Mf while Mf 
negative persons that also did not have lymphedema, but were positive 
for IgG4 antibodies to filarial antigen, were controls. Levels of specific 
IgG4 antibodies decrease after loss of Mf and adult worms within a few 
months in brugian and bancroftian filariasis [60, 136]. The loss of IgG4 
has been shown to correlate with the loss of antigen in bancroftian 
infections [137]. Therefore positivity in a non-quantitative dipstick assay 
of IgG4 is a reasonable indicator of ongoing infection. While not ideal, in 
the absence of an antigen test this is currently the only way, in addition to 
endemicity of filariasis to demonstrate LE due to brugian filariasis rather 
than another cause. On Alor, the prevalence of LE strictly follows the 
prevalence of brugian filariasis.  
In the IL-18 SNP set, LE cases and controls totaled 39 and 83, 
respectively. For the IL-4R SNP set, samples size was 83, 41 cases and 42 
controls. 
Genomic DNA was isolated from 400 µl blood (stored diluted 1:1 with 8M 
urea at 4 ºC) using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). 
DNA was eluted from the column in 200 µl AE buffer. For the IL-18 SNPs, 
genotyping was performed using TaqMan-based assays that were 
purchased from Applied Biosystems (Foster City, CA). The PCR was 
performed with a GeneAmp PCR system, model 9700 (Applied 
Biosystems). Fluorescence levels of the PCR products were measured with 
an ABI Prism model 7900 HT sequence detector (Applied Biosystems). The 
IL-4R SNPs were detected using the pyrosequencing technique at the 
Cologne Centre for Genomics in Cologne, Germany as previously 
described [138]. The pyrosequencing was performed in a Biotage PSQ HS 
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96A SNP system (Pyrosequencing AB, Uppsala, Sweden), and the data 
were captured with PSQ HS SNP software as described by Ronaghi [138]. 
 
2.7.4 Statistics 
 
For Hardy-Weinberg Equilibrium (HWE) calculations, including the 
inbreeding coefficient (Appendix II), the deFinetti online program from 
Strom and Wienker was used (http://ihg.gsf.de/cgi-bin/hw/hwal.pl). 
Baseline data were analyzed with the Stat View software (version 5.0) for 
Windows (SAS Institute Inc., Cary, NC, USA). Single-marker and 
haplotype analyses were done with the FAMHAP software 
(http://famhap.meb.uni-bonn.de/) as described previously [139]. In the 
single-marker analysis, an Armitage trend test (ATT) was used to test 
significant association of the single SNPs in cases and controls [140]. P 
values with P≤0.05 were considered to be nominally significant before 
adjustment for multiple testing. The expectation-maximization (EM) 
algorithm was used to estimate the maximum-likelihood haplotype 
frequencies [139, 141]. A likelihood-ratio test was used to assess 
significance of the haplotype distribution. To correct for multiple testing, 
the program performs simulations to obtain a P value that does not rely 
on asymptotic theory. To determine the corrected P value, FAMHAP 
performs an Omnibus statistic which permutes the disease status of the 
individuals for each simulated replicate such that the numbers of cases 
and controls are the same as in the original sample. Permutation with 
200,000 simulated replicates was done to obtain a corrected P value 
(Global P value) [142]. 
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3. Results 
 
3.1 Treatment of 4 and 6 weeks doxycycline in 
onchocerciasis  
 
3.1.1 Nodules 
 
To evaluate the efficacy of doxycycline against Wolbachia endobacteria as 
antifilarial therapy in onchocerciasis patients a randomized placebo-
controlled study was conducted.  
Patients were treated for 6 weeks with 200 mg/day doxycycline, 4 weeks 
doxycycline followed by 2 weeks matching placebo or matching placebo 
for 6 weeks. The aim was to study in a placebo controlled manner the 
efficiacy of 4- and 6-week treatment with doxycycline followed by IVM, in 
order to define a minimum regimen needed to achieve Wolbachia 
depletion. Second aim was to assess a potential macrofilaricidal activity of 
doxycycline on O. volvulus. 
To quantify the amount of Wolbachia in doxycycline and placebo treated 
patients, real-time PCR for the bacterial ftsZ gene was done. Since there 
is variation between nodules with regard to the amount of human tissue in 
relation to worms, the Wolbachia loads were normalized to O. volvulus β-
actin as described previously [143]. Nodules without a β-actin signal were 
not considered for further analysis. Depletion of Wolbachia after 
doxycycline, demonstrated by quantitative PCR, was observed at all 
follow-ups. At 6, 20 and 27 months the nodules from both doxycycline 
groups showed Wolbachia levels that were almost 10-fold lower than 
nodules from the placebo-treated group (Table 1). This was sustained 
over the observation period, with no indication of an increase. The median 
ftsZ/β-actin ratio at 20 and 27 months in the 6-week group is clearly 
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lower than in the respective 4-week treatment group (not significant), 
indicating a better doxycycline activity with the longer treatment duration. 
 
Table 1 Effect of doxycycline treatment on Wolbachia loads in worm 
tissuea: results of quantitative PCR 
a DNA was prepared from parts of onchocercomas extirpated at the indicated time points, and the 
copy numbers of the Wolbachia single copy gene ftsZ and the nematode gene β- actin were 
determined by quantitative PCR. 
b Median 
c Significant differences in the respective doxycycline compared to the placebo group (Mann-
Whitney-U test). 
No significant differences between the two doxycycline groups were observed at any time point. 
 
 
 
 
 
Treatment 
group 
 
Time 
(months) 
Number of 
patients/ nodules  
Index 
ftsZ / actinb 
(10-90th percentiles) 
P valuec 
Placebo 
 
6 12 /31 3.24 
(0.3-19.5) 
- 
 
 
20 
 
16 / 70 3.04 
(0.2-27.0) 
- 
 27 
 
7 / 19 1.85 
(0.1-29.1) 
- 
Doxycycline 
(4 weeks)    
20 
 
7 / 13 0.47 
(0.01-3.2) 
0.0016 
 27 
 
5/ 15 0·20 
(0.04-3.31) 
0.0011 
Doxycycline 
(6 weeks) 
6 10 / 33 0.19 
(0.02-4.4) 
0.0005 
 20 
 
12 / 22 0.30 
(0.04-6.9) 
<0.0001 
 27 
 
5 / 11 0.13 
(0.04-1.4) 
0.0004 
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3.1.2 Skin samples 
 
To determine the depletion of Wolbachia in skin Mf (PCR) and analyse the 
Mf content in the treated and untreated patients (microscopic analysis), 
skin biopsies near the site of the extirpated nodule were taken from all 
patients who were available for follow-up and underwent nodulectomy. 
Not all patients had enough skin material for both microscopic and PCR 
analysis. As IVM treatment affects skin Mf only patients who had taken 
IVM at 6 months after treatment were included for further analysis to 
have an identical treatment background. 
Table 2 presents the skin Mf load at all follow-ups by microscopic analysis. 
The results showed that at month 20, in the placebo group that had 
received only IVM, Mf loads were reduced (Table 2). Except one patient, 
all were positive for skin Mf. In contrast, in both groups that had received 
doxycycline plus IVM, the median Mf level was highly reduced, being zero 
in the 6-week doxycycline group 20 months after treatment compared to 
placebo. In both doxycycline groups, the proportion of patients, who were 
still positive for skin Mf, was significantly lower than in the placebo group. 
At month 27, the significant and sustained reduction of skin Mf as 
compared to placebo was still maintained in the 6-week doxycycline 
group. There was less reduction of skin Mf in the 4-week group, while in 
the placebo group, there was a clear resumption of Mf production, 
confirming earlier reports which show that production of Mf starts a few 
months after the administration of IVM [144, 145]. 
To assess Wolbachia levels in Mf after treatment with doxycycline, real-
time PCR measuring the amount of bacterial ftsZ and worm β-actin was 
performed. The PCR results showed that the remaining Mf contained 
almost 10-fold lower levels of Wolbachia at 20 months after treatment in 
the 4- and the 6-weeks group. In the 4-weeks doxycycline group at month 
20, the ratio ftsZ/β-actin was significantly lower compared to the 
respective placebo group. This can not be maintained, as at month 27, 
there is a ftsZ/β-actin ratio similar to that found in the placebo group. A 
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different picture is seen in the 6-weeks doxycycline group, were at month 
20 and 27 a significantly lower ftsZ/β-actin ratio can be observed (Table 
3). 
 
Table 2 Effect of doxycycline treatment on Mf loads in skin biopsies: 
results of microscopic analysis 
            (Published by Hoerauf et al., 2008) 
a Geometric mean intensity (GMI), median values, and ranges of Mf/mg skin are shown. The GMI 
was calculated using the log (x+1) method according to Williams. 
Histology examinations were done by S. Specht and D. W. Büttner as published [45].  
      
 
 
 
 
Treatment 
group 
 
 
Time 
(months) 
Number of 
patients 
assessed  
Mf levelsa 
GMI 
(range) 
Median Number of 
patients with 
skin Mf (% 
total) 
Placebo 
 
6 16 14.3 
(0-64) 
27.6 15 (94%) 
 
 
20 
 
18 4.4 
(0-58) 
4.3 17 (94%) 
 27 
 
15 5.5 
(0-75) 
3.0 12 (80%) 
Doxycycline 
(4 weeks) 
20 
 
10 0.7 
(0-6) 
0.3 6 (60%) 
 27 
 
10 1.3 
(0-23) 
0.4 5 (50%) 
Doxycycline 
(6 weeks) 
6 16 14.7 
(0.4-60) 
25.2 16 (100%) 
 20 
 
14 0.1 
(0-1) 
0.0 3 (15%) 
 
 27 
 
10 0.8 
(0-6) 
0.6 7 (70%) 
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Table 3 Effect of doxycycline treatment on Wolbachia loads in skin 
biopsies: results of quantitative PCR 
a Median 
b Significant differences in the respective doxycycline compared to the placebo group (Mann-
Whitney-U test). 
 
 
Treatment 
group 
Time 
(months) 
Number of 
patients/ skin 
snips  
Index 
ftsZ / actina 
(10-90th percentiles) 
P valueb 
Placebo 
 
6 16/25 0.04 
(0.0006-0.045) 
- 
 
 
20 
 
17/29 0.03 
(0.0018-0.15) 
- 
 27 
 
8/14 0.02 
(0.005-0.51) 
- 
Doxycycline 
(4 weeks)    
20 
 
8/18 0.004 
(0.0005-0.02) 
0.0009 
 27 
 
7/14 0.02 
(0.003-0.38) 
0.6800 
Doxycycline 
(6 weeks) 
6 12/19 0.004 
(0.0006-0.04) 
0.0003 
 20 
 
13/17 0.006 
(0.001-0.11) 
0.0209 
 27 
 
5/15 0.005 
(0.0005-0.03) 
0.0009 
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3.2 Treatment of 5 weeks doxycycline in onchocerciasis 
 
3.2.1 Nodules 
 
Previously, a treatment with 100 mg/day doxycycline administered for 6 
weeks was studied [41]. The aim of the present study was to investigate 
the effects of a shortened regimen of only 5 weeks doxycycline treatment 
on the depletion of Wolbachia endobacteria from O. volvulus. 
All palpable nodules of 20 doxycycline and ten untreated patients were 
excised and analyzed by histology, after excluding patients which could 
not take part in the study due to incomplete treatment or refusal of 
nodulectomy 
Out of the 20 doxycycline treated patients, 12 patients had enough tissue 
material for PCR analysis at 20 months after treatment (45 nodules), 
whereas of these, 10 were able to give PCR samples at 27 months after 
treatment (22 nodules). There were 9 untreated control PCR samples (23 
nodules). Compared to the untreated control group, at both follow-ups the 
nodules of the doxycycline treated group showed a significantly lower 
ftsZ/β-actin ratio (Table 4). There was also a significantly lower ratio at 
month 20 compared to month 27. These findings fit to the histology 
results. In doxycycline treated patients, 76% female and 62% male 
worms did not contain Wolbachia. Only 7% of the worms in the 
doxycycline treated group showed normal embryogenesis and 7% of the 
nodules had living Mf in the human tissue [46]. These Mf were found only 
adjacent to young productive Wolbachia-positive worms, which had 
probably been acquired after the end of treatment during the follow-up 
period [46, 146]. 
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Table 4 Effect of 5 weeks doxycycline treatment on Wolbachia loads in 
worm tissuea: results of quantitative PCR 
a DNA was prepared from parts of onchocercomas extirpated at the indicated time points, and the 
copy numbers of the Wolbachia single copy gene ftsZ and the nematode gene β- actin were 
determined by quantitative PCR. 
b Median 
c Significant differences in the respective doxycycline compared to the control group (Mann-
Whitney-U test). 
 
3.2.2 Skin samples 
 
As in the placebo controlled study, the decrease of Mf levels was first 
monitored by microscopic analysis (Table 5). Skin Mf levels were 
determined at 21 and 27 months after doxycycline treatment. Some 
patients only attended one of the follow-ups, therefore the available skin 
Mf value was taken for the analysis and gives a combined result of month 
21 and month 27. In the doxycycline treated group, 13 of the 21 patients 
had no Mf and the Mf load had decreased to 0.2 Mf/mg skin, indicating an 
interruption of Mf production by doxycycline alone since the last IVM 
intake was by then 31-43 months prior to the skin biopsy. As in the 
placebo controlled study, only patients who had not taken IVM more than 
two times prior to study onset were included.  
Since transmission in this area was not interrupted (R.Garms, Bernhard-
Nocht Institute, unpublished report, 2006), it is assumed that remaining 
Treatment 
group 
Time 
(months) 
Number of 
patients/ 
nodules 
Index  
ftsZ / actinb  
(10-90th 
percentiles)  
P valuec 
Control 27 9/23 1.88 
(0.33-6.92) 
 
Doxycycline 
(5 weeks)    
21 
 
12/45 0.08 
(0.011-1.24) 
<0.0001 
 27 
 
10/22 0.30 
(0.054-1.57) 
<0.0001 
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Mf are from female worms that are acquired after the end of doxycycline 
treatment. 
 
Table 5 Effect of 5 weeks doxycycline treatment on Wolbachia loads in 
skin biopsies: results of microscope analysis 
          (Published by Hoerauf et al., 2009)  
a Geometric mean intensity (GMI), median values, and ranges of Mf/mg skin are shown. The GMI 
was calculated using the log (x+1) method according to Williams 
 
Histology examinations were done by S. Specht and D. W. Büttner as published [46]. 
 
The PCR results show a significant decrease in bacterial ftsZ/β-actin ratio 
in the doxycycline treated group compared to the untreated control group 
at month 21 (Table 6). At month 21 the remaining Mf in the treated group 
had increased Wolbachia levels. At month 27 the median of the ratio 
ftsZ/β-actin was much lower than the median in the control or even the 
doxycycline group at month 21, but the range in some samples was 
higher than the control samples. Therefore no significant difference 
between the 27 months samples and the control samples can be 
observed. When combining the doxycycline values for month 21 and 
month 27, there was still a significant decrease in the ftsZ/β-actin ratio 
compared to the placebo group (P=0.022). 
 
 
 
 
 
Treatment 
group 
 
 
Time 
(months) 
 
Number of 
patients 
examined  
 
Number 
of Mf 
carriers 
Mf levelsa 
 
GMI 
(range) 
 
 
Median 
Control 27 10 10 43 
(5-597) 
55 
Doxycycline 
(5 weeks)    
21 or 27 
 
21 8 0.9 
(0-58) 
0.2 
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Table 6 Effect of 5 weeks doxycycline treatment on Wolbachia loads in 
skin biopsies: results of quantitative PCR 
a Median 
b Significant differences in the respective doxycycline compared to the control group (Mann-
Whitney-U test). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment 
group 
 
 
Time 
(months) 
Number of 
patients/ skin 
snips  
Index 
ftsZ / actina 
(10-90th 
percentiles) 
P valueb 
Control 27 9/18 0.04 
(0.004-0.15) 
 
Doxycycline 
(5 weeks)    
21 
 
11/12 0.01 
(0.001-0.14) 
0.004 
 27 
 
18/31 0.009 
(0.002-0.56) 
0.117 
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3.3 Treatment of 6 weeks azithromycin in onchocerciasis 
 
To analyse the efficacy of the antibiotic azithromycin to deplete Wolbachia 
endobacteria, a study with onchocerciasis infected patients was 
conducted. The azithromycin treatment was well tolerated by most 
participants.  A few patients complained of mild side effects. Four had 
diarrhoea and three had abdominal pain. None of the patients complained 
or presented severe adverse reactions.  
Beside histological examination of the extirpated nodules, some patients 
at 6 months after study onset had enough nodule material for an 
additional DNA extraction and PCR analysis for the Wolbachia ftsZ and the 
O.volvulus β-actin gene. 
 
Table 7 Effect of Azithromycin treatment on Wolbachia loads in worm 
tissue: results of quantitative PCR 
aMedian 
DNA was prepared from parts of onchocercomas extirpated at the indicated time points, and the 
copy numbers of the Wolbachia single copy gene ftsZ and the nematode gene actin were 
determined by quantitative PCR. 
 
 
Treatment group 
 
 
Time 
(months) 
Number of patients/ 
nodules  
Index 
ftsZ / actina 
(10-90th percentiles) 
Control 
 
0 9/14 11.84 
(1.87-62.8) 
Azithromycin 
250mg/day  
6 weeks   
6 
 
4/5 16.59 
(5.62-549.1) 
Azithromycin 
1200mg/week 
6 weeks 
6 2/4 31.08 
(5.50-67.03) 
 12 
 
8/32 63.13 
(6.97-749.4) 
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The PCR results did not show a significant decrease of the Wolbachia 
ftsZ/worm β-actin ratio compared to the control group, neither in the 250 
mg/day for 6 weeks nor the 1200/week for 6 weeks group at any time 
point. Median levels of the ftsZ/β-actin ratio showed even higher levels as 
in the control group (Table 7). 
Monitoring of Wolbachia expressed as ftsZ/β-actin ratio provided insight 
into the content after treatment at the molecular level. Histological results 
revealed that the Wolbachia loads of the worms were not different from 
those of the untreated group at 6 months after treatment. Also, the Mf in 
the skin biopsies taken 6 months after azithromycin treatmen still 
contained Wolbachia. In contrast, 12 months after administration of the 
250 mg/day azithromycin regimen, the worms presented a significantly 
reduced Wolbachia load analysed by histology: only 65% of the living 
female filariae contained many (>50) endobacteria compared to 92% in 
untreated living females [147]. At this time point no samples for PCR were 
left for that group to confirm these results with PCR.  
In conclusion, by histological analysis a reduction of Wolbachia after 6-
weeks daily azithromycin treatment could be observed, but no depletion 
as confirmed by PCR. It is further concluded from the histological data, 
that 6-weeks azithromycin treatment does not reduce or interrupt the 
embryogenesis of O.volvulus.  
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3.4 Treatment of W. bancrofti infection with rifampicin 
and/or doxycycline 
 
To evaluate the efficacy of the antibiotic substance rifampicin on 
Wolbachia depletion in LF with several treatment durations and dosages, 
W. bancrofti infected patients were included in an open trial. 
Fourtyeight men were randomized and 39 patients completed the study. 
Of the 48 men, 12 were treated with 200 mg doxycycline/day for 4 weeks, 
16 were treated with a combination of 200 mg doxycycline/day + 
10mg/kg/day rifampicin for 2 weeks and 11 patients received placebo 
matching doxycycline. Nine patients did not complete the allocated 
intervention, three from the doxycycline 4 weeks arm, one from the 
doxycycline+rifampicin combination and five from the placebo group 
(Figure 15).  
Table 8 illustrates the changes in microfilaremia and Wolbachia/Mf from 
baseline and at follow-up 4 months after treatment. Baseline 
measurements were similar between the allocated treatment groups, 
except Mf load which was higher in placebo group than in the two 
treatment groups. However, Mf loads between the 4-week doxycycline 
group and the 2-week doxycycline+rifampicin group were comparable 
(Table 8). 
At 4 months post treatment, Wolbachia ftsZ copies/Mf were reduced by 
94% (P=0.002, Wilcoxon Rank test) in the 4-week doxycycline group, 
followed by 86% reduction (P=0.034, Wilcoxon Rank test) in the 2-week 
rifampicin+doxycycline group. There was no significant change in the 
placebo group (P=0.138); rather, values had a trend to increase. At 12 
and 24 months after treatment, Mf in the 4-week doxycycline group were 
only detectable via microscope in a few samples (1-4 Mf positive 
patients). Therefore we excluded PCR at these follow-ups because PCR 
results of only one patient would not be comparable to the other 
treatment groups.  
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Additional results [121] 
At 12 months after treatment, the 4-week doxycycline treatment 
completely reduced the Mf load (P=0.012). Significant reductions in 
microfilaremia were also seen in the 2-week doxycycline+rifampicin 
(P=0.003) and placebo (P=0.043) regimens. However, at 18 and 24 
months, while the 4-week doxycycline group and 2-week 
doxycycline+rifampicin regimens continued to maintain significantly low 
microfilarial loads, there was a rise in Mf loads in the placebo patients. 
Measurement of adult worm vitality with USG showed that at 12 months 
follow up, the 4-week doxycycline group had no change in worm vitality. 
The same trend could be seen in the number of FDS. While there was a 
decrease of FDS in the doxycycline and the combination group, there was 
rather an increase in the placebo group. At 18 months after treatment, 
this pattern remained the same with the 4-week doxycycline group having 
100% loss of worm nests, the 2-week doxycycline+rifampicin group 
showing a 50% loss of worm nests while the placebo group remained 
unchanged. This trend was also observed at 24 months follow up but was 
less significant. 
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Table 8 Primary variables measured before and after doxycycline and 
rifampicin treatment 
4 weeks Doxycycline  Before 
treatment  
4 months 
Number of MF-positive individuals/all (%) 12/12 (100%) 9/12 (75%) 
P valueb  P=0.515 
Median of Microfilaraemiaa 523 (154 - 1013) 307 (12 - 1068) 
P valueb  P=0.388 
Median Wolbachia load/Mfa 167 (71 – 238) 11 (4 – 24) 
P valueb  P=0.002 
2 weeks Rifampicin plus Doxycycline    
Number of MF-positive individuals/all (%) 12/12 (100%) 10/12 (83%) 
P valueb  P=1.0 
Median of Microfilaraemiaa 392 (122 - 460) 394 (39 – 703) 
P valueb  P=0.695 
Median Wolbachia load/Mfa 121 (95 – 200) 18 (7 – 52) 
P valueb  P=0.034 
4 weeks placebo matching Doxycycline    
Number of MF-positive individuals/all (%) 5/5 (100%) 5/5 (100%) 
Median of Microfilaraemiaa 2380 (1230 – 
3680) 
2585 (412 – 
3738) 
P valueb  P=0.686 
Median Wolbachia load/Mfa 133 (85 – 164) 358 (100 – 879) 
P valueb  P=0.138 
a Median with 25th-75th percentile                       (Published by Debrah et.al, 2011) 
b Wilcoxon Rank test 
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3.5 Retarded O. volvulus L1 to L3 larval development in the 
Simulium damnosum vector after anti-wolbachial 
treatment of the human host 
 
3.5.1 Selection of Simulium capture side 
 
In selecting a capture site, we determined the natural parous and infection 
rates by collecting and dissecting wild Simulium flies. A total of 1722 flies 
were dissected, 19.6% were parous and 0.001% infected. 
 
3.5.2 Kinetics of larval development 
  
To determine the skin microfilarial loads and recovery of O. volvulus 
larvae from flies that had fed on doxycycline or placebo treated 
individuals, skin biopsies and dissected flies were analyzed for developing 
larvae. Mf were counted and expressed as Mf per skin biopsy (Table 9). 
The total number of larvae (L1, L2, and L3) collected after dissection from 
the flies was calculated. The proportion of each larval stage that 
developed at each follow-up in each group was generated by dividing the 
larval number (L1+L2 or L3) by the total number of larvae for each time 
point (Figure 19). The proportions were plotted against the month of 
dissection (month post-treatment) to follow the kinetics of larval 
development in both groups. Starting 3 months post-treatment, 
differences in the median recovery of L1+L2 and L3 from flies fed on the 
doxycycline treated volunteers were seen. The proportions of L1+L2 
larvae recovered from flies that had fed on doxycycline treated individuals 
were significantly higher (P<0.05, Mann-Whitney U test) at 3 and 5 
months post-treatment compared to placebo (Figure 19). 
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Table 9 Median larval recoveries from skin and blood-fed black flies of 
doxycycline and placebo volunteers 
 
Treatment 
 
Doxycycline n=7 (200mg/day 6 weeks) 
  
Month of the 
study 
0 1 2a 3 4 5 
Mf/skin snipb 26 
(13-62) 
43  
(32-98) 
40  
(8-78) 
13  
(7-35) 
9  
(2-111) 
28  
(4-70) 
L1+L2 larvae 
stageb 
52  
(45-122) 
29  
(3-101) 
130  
(28-365) 
678 
(167-941) 
297  
(103-343) 
426  
(201-
1177) 
L3 larvae 
stageb 
703  
(509-949) 
281  
(150-554) 
797  
(211-1354) 
709  
(335-935) 
318  
(71-549) 
53  
(44-209) 
  
Placebo n=5 
    
Mf/skin snipb 25  
(10-70) 
83  
(41-178) 
114  
(15-162) 
27  
(10-97) 
63  
(9-88) 
63  
(4-209) 
L1+L2 larvae 
stageb 
124 
 (71-147) 
33  
(7-67) 
112  
(42-244) 
390  
(90-761) 
217  
(118-531) 
575  
(388-926) 
L3 larvae 
stageb 
789  
(396-923) 
313  
(226-469) 
666 
(385-855) 
983  
(487-
1126) 
406  
(247-530) 
240  
(116-433) 
a Median of larval recovery with range 
b At 2 months post treatment only 6/7 doxycycline treated volunteers attended the follow-up 
meeting 
 
Correspondingly, at 3 and 5 months post-treatment a significant decrease 
(P<0.05, Mann-Whitney U test) in the proportion of L3 that developed in 
flies that had fed on doxycycline treated individuals as compared to 
placebo treated individuals was observed (Figure 19).  
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Figure 19 Larval proportions 
The proportion of larvae at each stage was calculated by dividing the number of larvae (stage 
L1+L2; L3) by the total larvae collected from the captured blackflies after they had fed on the 
doxycycline (n=7) or placebo (n=5) treated volunteers. A) The proportion of L1+L2 larvae in flies 
that had fed on doxycycline treated individuals (black bars) was higher beginning at 3 months 
post-treatment compared to placebo.  
BThe proportion of L3 larvae in flies that had fed on doxycycline treated volunteers (grey bars) was 
lower than that in the placebo volunteers at months 3,4 and 5 post-treatment. Proportions are 
given as percentages of median larval recovery. A 100% correspond to the total number of larvae 
recovered at the indicated timepoint. 
 
3.5.3 Wolbachia depletion after treatment with doxycycline 
 
To analyse the effect of antibiotic treatment on the bacterial 
endosymbionts of O. volvulus Mf from the skin and larvae isolated from 
the vector, a quantitative real-time PCR assay was established for the O. 
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volvulus Wolbachia ftsZ gene. For normalization to worm material in the 
individual sample, a second PCR assay for O. volvulus β-actin was done.  
Compared to the placebo group, fewer samples were positive for ftsZ 
above the PCR detection limit in the Mf of doxycycline treated individuals 
at 2, 3, 4 and 5 months post-treatment. Analysis of the Mf that had 
emerged from skin biopsies showed a greater than 50% reduction in the 
number of Wolbachia one month post-treatment in the doxycycline 
treated group (Table 10). Wolbachia reduction further increased to 81% in 
the follow-up time points. At the two month follow-up only two of the six 
Mf samples (33%) gave a positive ftsZ signal in the PCR which further 
decreased to only one ftsZ positive sample (14%) at the 5 months follow-
up. A similar pattern was seen in all larval stages collected from the 
vector. In contrast, in the placebo group, almost every larval stage at 
each time point produced a clear signal for bacterial ftsZ. Only two 
placebo samples (L1 at pre-treatment and L2 at month 2 post-treatment) 
did not have a positive signal above the detection limit for ftsZ. These 
samples also gave a weak signal for actin (data not shown), indicating a 
very low DNA content. For all samples, an inhibition test PCR with a 
mouse IFN-γ plasmid did not show any inhibition by the sample DNA. The 
negative ftsZ samples therefore did not result from any inhibitory factors 
in the DNA. 
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Table 10 Effect of doxycycline and placebo treatment on Wolbachia loads  
in larval worms: results of quantitative PCR 
Doxycycline 
(200mg/day 6 weeks) 
Number of Wolbachia ftsZpositive volunteers for  
the indicated larval stages (median ftsZ/β-actin ratio) 
Month of the Study MF skin L1 (Mf vector) L2 L3 
0 (pre-treatment) 7/7 (0.06) 7/7 (0.058) # 6/6 (0.026) 
1 6/7 (0.024) 4/7 (0.002) # 3/7 (0.008) 
2 2/6 (0.068) 0/6 1/6 (0.007) 2/6 (0.011) 
3 2/7 (0.131) 2/7 (0.06) 4/7 (0.029) 4/7 (0.059) 
4 3/7 (0.085) 0/7 3/7 (0.002) 2/7 (0.036) 
5 1/7 (0.167) 3/7 (0.001) 1/7 (0.002) 3/6 (0.017) 
Placebo     
0 (pre-treatment) 5/5 (0.02) 4/5 (0.03) # 5/5 (0.05) 
1 4/4 (0.05) 5/5 (0.06) # 5/5 (0.03) 
2 5/5 (0.22) 5/5 (0.11) 4/5 (0.06) 5/5 (0.05) 
3 4/4 (0.70) 5/5 (0.41) 5/5 (0.16) 5/5 (0.19) 
4 5/5 (0.30) 4/4 (0.32) 4/4 (0.16) 5/5 (0.43) 
5 5/5 (0.56) 3/3 (0.08) 4/4 (0.09) 5/5 (0.12) 
# L1 and L2 counts were combined at months 0 and 1 of the study 
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3.6 Detection of the HhaI gene in infection with B. malayi 
by real-time PCR 
 
3.6.1 PCR validation 
 
To establish a method for detection of parasite DNA in human infection 
with B. malayi, especially cryptic (pre-patent or latent infections), PCR for 
HhaI was used to measure parasite DNA from plasma. Using the 
Quantitect® Probe master mix and a plasmid standard dilution series, the 
efficacy of the reaction was >85%. In 100% of the samples, 200 copies/µl 
could be detected. In 85% of the samples 22 copies could be detected. 
This was set as the detection limit of the PCR with 2 µl sample DNA 
(Figure 21). For samples which were below the detection limit for HhaI in 
the 2 µl assay, a second PCR with the QuantiTect® Virus mastermix using 
10 µl of DNA was done. A plasmid standard dilution series showed that the 
sensitivity with the 10 µl assay could be decreased down to 2 copies/µl 
and the reaction efficacy reached 100% (Figure 22). Each PCR replicate 
used 10 µl of diluted plasmid as DNA target in a final 20 µl reaction 
volume with the QuantiTect® Virus NR Master Mix. At the lowest dilution 
(2 copies/µl) 50% of the samples were detected. 100% of the samples 
were detected beginning with the 20 copies/µl. 
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Figure 21 Detectionlimit HhaI PCR 2 µl Assay 
The detection limit of the HhaI PCR was determined with a plasmid dilution series using 2-2000 
copies/µl. Each sample contained 2 µl of diluted plasmid in a final reaction volume of 20 µl using 
the QuantiTect® Probe PCR Master Mix, Qiagen. In the lowest dilution (2 copies/µl), no signal was 
detected. In the second lowest (20 copies/µl) 85% of the samples gave a positive signal. With the 
200 copies/µl dilution, 100% of the plasmid samples were detected. The PCR reaction efficacy was 
85%. 
The standard curve is shown with standard error of mean. 
 
 
 
2000  200 20 Copies/µl 
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Figure 22 Detection limit HhaI PCR 10 µl Assay 
Each PCR replicate used 10 µl of diluted plasmid as the DNA target in a final 20 µl reaction volume. 
At the lowest dilution (2 copies/µl) 50% of the samples were detected. 100% of the samples were 
detected beginning with the 20 copies/µl.  
The standard curve is shown with standard error of mean. 
 
 
 
 
 
 
 
 
2 copies/µl 20 200 
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3.6.2 Detection of the HhaI gene in B. malayi infected jirds by real-time 
PCR 
 
To validate the HhaI PCR assay used for detection of B. malayi infection in 
plasma, the real-time QuantiTect® PCR assay was used on plasma taken 
eight weeks after infection from nine infected and nine naive jirds. No Mf 
could be found at this time indicating a pre-patent status. Patent B. malayi 
infections in jirds can usually be detected 75-110 days after infection 
[129]. All infected jirds were confirmed to have adult worms (Median=9, 
range=9-76) when the animals were necropsied. 
 
Table 12 HhaI detection in plasma from pre-patent jirds (56 days post  
infection) 
 
a Median (range) 
 
The B. malayi HhaI PCR assay detected a positive signal in all infected 
jirds, but was negative in plasma samples from uninfected jirds (Table 
12). The results confirmed the sensitivity of the HhaI PCR in pre-patent, 
amicrofilaremic samples. 
 
3.6.3 DNA extraction from plasma used as negative/positive controls 
 
To validate the PCR, 30 Mf positive and 9 elephantiasis (latent infected) 
samples from patients from Central Sulawesi were measured (Table 13). 
In the nine elephantiasis patients, only one was Mf positive. Additionally, 
10 plasma samples of European blood donors, 19 samples with different 
parasite infections and 10 plasma samples from another study in Ghana 
Animal group HhaI positives Adult worm recoverya 
infected jirds 9/9 40 (9-76) 
uninfected jirds 0/9 0 
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with W. bancrofti infected patients were also tested with the HhaI PCR 2 
and 10 µl assays (Table 14). 
Table 13 Positive control validation HhaI PCR Sulawesi, Indonesia 
 
a 2 µl of sample DNA was used in the PCR 
b 10µl of sample DNA was used in the PCR 
 
Table 14 Negative control validation 
 2 µla 10 µlb % 
W. bancrofti 
Mf positive patients 
0/10 0/10 0 
Toxocara spec. 0/4 0/4 0 
Schistosoma spec. 0/5 0/5 0 
Strongyloides stercoralis 0/4 0/4 0 
Dirofilaria repens 0/2 0/2 0 
European blood donors 0/10 0/10 0 
 
a 2 µl of sample DNA was used in the PCR 
b 10µl of sample DNA was used in the PCR 
 
In all Mf positive samples, detection of the HhaI gene was successful. In 
the elephantiasis group, first PCR with the 2 µl assay gave 100% positive 
detection, although only one patient was Mf positive with one Mf/ml. In a 
second PCR only 7/9 were positive in the PCR (Table 13). This is due to 
the low amount of parasite DNA in the sample, which is in a range were 
the rate of detection is 85% in the 2 µl assay. In the following 10 µl 
assay, all samples of the elephantiasis group were positive. In the 
samples used as negative controls (Table 14) there was no positive 
detection of the HhaI gene, confirming the specificity of the assays. 
 
Mf positive patients PCR positive 2 µla % PCR positive 10 µlb % 
30/30 30/30 100 30/30 100 
Elephantiasis patients    
Mf+ n=1 Mf- n=8 7/9 78 9/9 100 
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3.6.4 Plasma from B.malayi infected patients from Indonesia and 
threshold determination 
 
After validating the assays, the real-time PCR was used to detect parasite 
DNA in a transmigrant population, compared to life-long residents in a 
region endemic for B. malayi. There were 229 plasma samples of a 
transmigrant population in South Sulawesi and 105 plasma samples of 
life-long residents (LLR) measured for the HhaI gene of B.malayi (Table 
15). All of the 19 Mf positive patients were positive by the HhaI PCR 
assay, whereas only 17/19 (89.5%) had previously been detected by the 
IgG4 ELISA test (Figure 23). 
Compared to the IgG4 antibody tests, which are based on an IgG4 ELISA 
using crude extract with adult worm antigen or BmR1 antigen, the HhaI 
PCR showed a higher level of detection at all time points, even in 
transmigrants that had been in the endemic area only a few months at the 
time of sampling (Table 15). 
Conversely, there were 42 HhaI negative samples of which 19 were IgG4 
positive, arguing for previous exposure to B. malayi and against latent 
infection (Figure 23 and 24). 
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Figure 23 Flow Chart HhaI and IgG4 ELISA 
 
 
 
Figure 24 Flow Chart HhaI and IgG4 dipstick BmR1 
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Table 15 Detection of B. malayi HhaI in transmigrants and life-long residents in South-Sulawesi, Indonesia 
 
Length of 
residence 
 
 
Cases 
 
Children/ 
Adultsa 
 
Mf 
prevalence 
 
HhaI 
prevalence 
(%) 
IgG4 
prevalence 
(%) 
SWA-ELISA         
IgG4 + 
SWA-ELISA/ 
HhaI+ b 
IgG4 
prevalence 
(%) 
BmRI 
IgG4 + 
BmR1/ 
HhaI + b 
 
< 1 
month 
 
17 
 
3/14 
 
- c 
 
14/17 (82) 
 
0/17 (0) 
 
0/14 
 
0/17 (0) 
 
0/14 
 
2-4 
months 
 
33 
 
10/23 
 
- c 
 
25/33 (76) 
 
3/33 (9) 
 
 
2/25 
 
0/33 (0) 
 
0/25 
 
3 years 
 
 
67 
 
34/33 
 
0d 
 
58/67 (87) 
 
18/67 (27) 
 
 
18/58 
 
5/67 (7) 
 
5/58 
 
4 years 
 
 
52 
 
19/33 
 
0e 
 
50/52 (96) 
 
24/52 (46) 
 
 
22/50 
 
6/52 (12) 
 
6/50 
 
5 years 
 
 
19 
 
8/11 
 
0 
 
16/19 (84) 
 
11/19 (58) 
 
 
9/16 
 
8/19 (42)f 
 
7/16 
 
6 years 
 
 
41 
 
20/21 
 
5 
 
34/41 (83) 
 
23/41 (56) 
 
 
19/34 
 
17/41 (41)g 
 
16/34 
 
LLR 
 
 
105 
 
71/34 
 
14e 
 
95/105 (90) 
 
87/105 (83) 
 
 
77/95 
 
42/105 (40) 
 
40/95 
 
Total 
 
 
334 
 
165/169 
 
19 
     
a Children < 15 years, adults 16 years+ 
b match of IgG4 (SWA/BmR1) to HhaI PCR results 
c for logistic reasons blood was collected during daytime in 2 villages, therefore Mf counts are absent 
d Mf prevalence in the 3-year residents could be determined in 20 individuals only 
e one patient with unknown Mf status was included 
f 3 individuals were positive for IgG4 BmR1 and HhaI PCR, but negative for SWA-ELISA 
g 4 individuals were positive for IgG4 BmR1 and HhaI PCR, but negative for SWA-ELISA 
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Defining Mf+ (Central Sulawesi and transmigrants) and LE samples as 
having/having had an active infection, the Mf numbers significantly 
correlated with HhaI copies/µl (r=0.52, P<0.001, Spearman rank 
correlation). The linear regression line from the correlation crossed the Y-
axis at 47.31 HhaI copies/µl (SD=1.43) (Figure 25). The threshold of 
active infections  was calculated  to be 53.03 HhaI copies/µl (Y-intercept 
plus 4 SD) [148].  
 
 
Figure 25 Determination of a threshold for active infection 
Mf loads from Mf+ and LE patients were correlated to HhaI copies/µl (n=58). Linear regression was 
performed to calculate the Y-intercept and standard deviation of the line. The threshold was 
defined as: Y-intercept (47.31) + 4xSD (1.42). Spearman Rank correlation resulted in r=0.52 with 
P<0.001. 
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Figure 26 ROC-curve 
Individual samples were scored positive (Mf positive, LE) or negative (transmigrant samples of the 
≤ 1 month and 2-4 months group). The blue line represents the ROC-curve with sensitivity on the 
Y-axis and 1-Specificity on the X-axis. Dashed lines represent the intercept on the curve when 53 
HhaI copies are used as threshold. 
 
ROC-curve analysis confirmed that this threshold had good discriminatory 
power (AUC=0.854) with asymptotic significance (P<0.001). The AUC 
value represents the propability that the assay result for a randomly 
chosen positive case (active infection) will exceed the result of a randomly 
choosen negative case (larval exposure). Using this criterion, assay results 
of >53 HhaI copies/µl are classified as positive (active infection), which 
leads to a sensitivity of 0.741 and 1-specificity of 0.20 (Figure 26, Table 
16). Thus approximately 74.1% of all samples with active infections would 
be correctly identified as such (Sensitivity), and 20% of all samples with 
larval exposure would be incorrectly identified as active infections.  
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Table 16 Coordinates of the ROC-curve 
HhaI Threshold Sensitivity 1 - Specificity 
43,50 ,81 ,24 
45,50 ,79 ,24 
47,00 ,78 ,24 
50,00 ,74 ,24 
53,50 ,74 ,20 
56,00 ,72 ,20 
58,50 ,71 ,20 
61,00 ,71 ,18 
66,00 ,71 ,16 
70,50 ,69 ,16 
72,00 ,69 ,14 
80,00 ,67 ,14 
88,00 ,66 ,14 
90,00 ,64 ,14 
95,50 ,64 ,12 
106,00 ,62 ,12 
119,00 ,60 ,12 
126,50 ,59 ,12 
128,00 ,59 ,10 
150,50 ,57 ,10 
179,50 ,55 ,10 
200,50 ,52 ,10 
 
 
We therefore used 53 HhaI copies as threshold to differentiate patients 
with an active infection (persons with adult worms) from those who only 
had been exposed to infective larvae. 
 
To better understand what the real-time PCR was detecting and to use the 
calculated threshold to discriminate between active infections and those 
who were exposed to larvae, a more detailed analysis was performed by 
quantifying the HhaI gene in the transmigrant samples and sorting by 
time in the endemic region. In the group present in the endemic area for 
less than one month, 85.7 % of the HhaI positive individuals had <53 
HhaI copies/µl. Similar levels were seen in the 2-4 month group (68%) 
(Table 16, Figure 27).  
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Figure 28 Stratification of B. malayi HhaI copies/µl in transmigrants and 
life-long residents. 
Transmigrants resident <3 years had significantly fewer HhaI copies/μl than those resident >4 
years, which had HhaI loads similar to LLR. 
*Cochran-Armitage test for trend P<0.001 
 
Comparing the transmigrants resident in the endemic area less than 4 
years to those resident for 4-6 years, there was a significant increase in 
HhaI copy numbers in the latter group (Cochran-Armitage test for trend 
P<0.001) (Figure 28). The percentage of transmigrants resident in the 
endemic area for at least 3 years with >53 HhaI copies/µl was increased 
(54-100 copies/µl: 14% at 3 years to 32% at 4 years; 101-200 copies/µl: 
9% at 3 years to 28% at 4 years) (Table 17). 
 
* 
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Table 17 B. malayi HhaI copies/µl in transmigrants and life-long residents 
Time of 
residence 
(HhaI copies/µl 
median, range) 
 
 
HhaI copies/µl 
 
 
 
total 
 negative <53 54-
100 
101-
200 
201-
500 
501-
1000 
> 
1000 
 
< 1 month 
10 (0-1476) 3 12 0 0 0 0 2 17 
IgG4 ELISA 
positive 
0 0 0 0 0 0 0 0 
IgG4 BmR1 
positive 
0 0 0 0 0 0 0 0 
2-4 months            
9 (0-988) 
8 17 4 1 1 2 0 33 
IgG4 ELISA 
positive 
1 1 0 1 0 0 0 3 
IgG4 BmR1 
positive 
0 0 0 0 0 0 0 0 
3 years                  
18 (0-500) 9 41 8 5 4 0 0 67 
IgG4 ELISA 
positive 
0 12 2 2 2 0 0 18 
IgG4 BmR1 
positive 
0 3 1 0 1 0 0 5 
4 years                  
84 (0-515) 
2 14 16 14 5 1 0 52 
IgG4 ELISA 
positive 
2 5 8 7 2 0 0 24 
IgG4 BmR1 
positive 
0 2 2 1 1 0 0 6 
5 years          
67 (0-3057) 
3 4 6 2 1 2 1 19 
IgG4 ELISA 
positive 
2 3 3 1 0 1 1 11 
IgG4 BmR1 
positive 
1 2 2 1 1 1 0 8 
6 years    
60 (0-808) 
7 10 13 6 4 1 0 41 
IgG4 ELISA 
positive 
4 5 9 3 2 0 0 23 
IgG4 BmR1 
positive 
1 2 7 3 3 1 0 17 
LLR 
82 (0-4137)                   
10 31 19 23 12 5 5 105 
IgG4 ELISA 
positive 
10 27 14 18 10 4 4 87 
IgG4 BmR1 
positive 
2 13 6 8 8 2 3 42 
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The number of individuals with >53 copies/μl was significantly higher in 
the individuals resident for 4-6 years (P<0.001 Fisher’s exact test) 
compared to the group resident fewer than 4 years (Table 18). 
The IgG4 positive rate in the first three years tested by SWA-ELISA was 
18% and 4.3% by dipstick BmR1, whereas the PCR detected 83% of 
samples (Table 18).  
 
Table 18. Transmigrant population divided into two groups by length of 
residence in the B. malayi endemic area – positive and negative 
individuals for HhaI compared to IgG4 results 
 
a IgG4 0-3 years vs. 4-6 years P<0.001 (Fisher’s exact test) 
 
Of the 82% SWA-ELISA and 95.7% BmR1 IgG4 negative samples, >80% 
were positive for HhaI in the first three years. The number of IgG4 
positive individuals had significantly increased (51.8% in SWA-ELISA; 
27.7% in BmR1) for patients resident in the endemic area longer than 
four years, while the detection of HhaI positive samples remained high 
(89.3%) (Table 18). These data indicate that in Mf negative individuals, 
the PCR has a higher rate of detection than IgG4 serology in 
transmigrants.
Time of residence in the B. malayi endemic area 
 0-3 years n (%) 
n=117 
 4-6 years n (%) 
n=112 
 
 positive negative positive negative 
 
HhaI 
 
 
97 (82.9) 
 
20 (17.1) 
 
100 (89.3) 
 
12 (10.7) 
 
IgG4 (SWA)a 
 
 
21 (17.9) 
 
96 (82.1) 
 
58 (51.8) 
 
54 (48.2) 
 
IgG4 (BmRI)a 
 
 
5 (4.3) 
 
 
112 (95.7) 
 
31 (27.7) 
 
81 (72.3) 
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3.7 Genetic associations in brugian filariasis analyzed in 
patients from Alor Island, Indonesia 
 
3.7.1 Baseline 
 
In a previous parasitological study in the village of Mainang, 586 persons 
(37% of the population) were examined for pathology and blood was 
collected to determine microfilaremia and for genotyping. No significant 
differences in the rate of microfilaremia or lymphatic pathology were seen 
between those persons that were asked to participate during a house-to-
house visit or those that voluntarily came to the central health center 
when requested by local health workers [133]. Of those taking part in the 
survey, 157 (27%) patients were Mf positive (Table 19) and 77 (13%) had 
LE pathology (Table 20). In total, 30 SNPs were analyzed for association 
to different phenotypes in LF (Mf/LE) (Appendix II). Four SNPs, two in the 
IL-18 gene and two in the IL-4R gene were found to have an association 
with LF and were further analyzed. 
In the Mf dataset, the number of males and females with Mf was 80 and 
77, respectively (Table 19). The mean number of Mf per ml blood was 194 
Mf/ml (median 118 Mf/ml, range 0-4700 Mf/ml) in males and 173 Mf/ml 
(geometric mean 160 Mf/ml, range 0-6028 Mf/ml) in females, and was not 
significantly different (Mann-Whitney U test, P=0.238) [133]. After 
excluding patients with LE and absent IgG4 titer, only Mf-positive (cases) 
as well as Mf-negative but IgG4 positive patients (controls) were 
genotyped for the IL-4R SNPs. The numbers of males and females with Mf 
were 28 and 13, respectively. Males had a mean microfilarial level of 872 
Mf/ml (median 303, range 100-4700) and females had a mean 
microfilarial level of 1231 Mf/ml (median 1100, range 201-3964). The 
difference in Mf/ml between males and females was not significant (Mann-
Whitney U test, P=0.146).  
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Table 19 The age and sex distribution of microfilaremic and control 
patients genotyped 
Group No.of patients Males Females 
examined for pathology1 586 240 346 
Microfilaremic  
(Mf+) patients1 157 80 77 
Mean No. of Mf/ml 
(median; range)1   
194 
(118; 0-4700) 
173 
(160; 0-6028) 
Inclusion of LE negative, 
IgG4 positive 83 50 33 
Microfilaremic patients (Mf+) 41 28 13 
Mean No. of Mf/ml 
(median; range)  
1225 
(100-4700) 
872 
(303; 100-4700) 
1231 
(1100; 201-3964) 
Amicrofilaremic patients 
(Mf-) 42 22 20 
1published by Supali et al., 2002 
 
In the LE dataset, the number of males and females with LE was 28 and 
49 respectively (Table 20) [133]. After excluding related individuals and 
people negative for filarial specific IgG4 antibodies, only patients with LE 
pathology (cases, n=39) and patients without LE pathology, but IgG4 
positive (IgG4+, controls, n=83) were genotyped for the IL-18 SNPs. In 
both groups, Mf positive and Mf negative patients were included.  
There were 22 females and 17 males with LE stage 2-4 (Mann-Whitney U 
Test, P=0.944) (Table 22).  
Calculation of the inbreeding coefficient F (deviation from HWE) for the IL-
18 and the IL-4R SNPs did not give evidence for first-degree relations in 
the case or the control groups (Table 21 and 22).  
Both SNP datasets passed quality control parameters in FAMHAP including 
a missing rate below 5 %. 
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Table 20 The age and sex distribution of LE and control patients 
genotyped 
Group No.of patients males females 
examined for pathology1 586 240 346 
Patients with LE pathology1 77 28 43 
Inclusion of unrelated LE and IgG4 positive 39 17 22 
LE negative IgG4 positive 83 50 33 
1published by Supali et al., 2002 
 
3.7.2 Single Marker analysis for IL-4R 
 
Polymorphisms in the IL-4R gene were compared between the Mf positive 
and the Mf negative phenotype in LF. Two SNPs in the IL-4R gene (rs 
1805010 and rs1049631) were analyzed using the FAMHAP program 
performing a single marker analysis to calculate P values with an Armitage 
trend test (Table 21). Of the 41 Mf positive patients, two samples failed in 
the sequencing procedure leaving 39 samples for the association analysis.  
The ancestral genotype for Ile50Val SNP (rs 1805010) is A/A, coding for 
the aminoacid isoleucine. An A to G missense mutation results in the 
aminoacid valine at this position and has been associated with reduced IL-
4R activity [111]. In our study population, 17 Mf positive patients (43%) 
carried the G/G genotype coding valine, 16 patients (41%) were 
heterozygous and 6 (15%) carried the ancestral A/A genotype coding 
isoleucine. In the control group, the homozygous G/G genotype was 
detected in 9 individuals (21%), 22 (52%) were heterozygous and 11 
(26%) were homozygous for the ancestral A/A genotype. The genotype 
differences between Mf positive cases and Mf negative controls was 
significant P=0.0395 with frequency of allel G being 0.64 in Mf cases 
compared to 0.48 in the control group (Table 21). The Odds ratio for the 
G allele was 2.37 (CI: 1.12-5.02). 
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Table 21 Statistical results of Ile50Val SNP (FAMHAP and deFinetti) 
 MF cases n=39 Control (Mf-) n=42  
Genotype frequency1 (%) f_al G2 frequency1 (%) f_al G2 P ATT3 
G/G 17 (43) 0.64 9 (21) 0.48 0.0395 
G/A 16 (41) +/-0.057 22 (52) +/- 0.053  
A/A 6 (15)  11 (26)   
F (inbreeding) 4 0.10  -0.05   
P (Pearson 1df) 5 0.49  0.74   
1 Genotype frequency  
2 Frequency of allele G (FAMHAP)  
3 Armitage's trend test (FAMHAP) 
4 Inbreeding coefficient, deviation from HWE (deFinetti) 
5 Pearson’s goodness-of-fit chi-square (degree of freedom=1) (deFinetti) 
 
For the +3111 SNP in the 3’UTR region the genotype frequency between 
cases and controls was significantly different P=0.0145 (Table 22). In the 
Mf positive group, 26 patients (66%) carried the ancestral G/G genotype 
and 13 patients (33%) were heterozygous. In the control group, 18 
individuals (42%) were homozygous G/G and 21 individuals (50%) 
showed the heterozygous genotype (Table 22). The frequency of the G-
Allel was 0.83 in Mf cases compared to 0.68 in the Mf negative control 
group with Odds ratio for the G allele being 2.36 (CI: 1.17—5.02). 
Although both groups were in HWE, the A/A genotype was found only in 3 
control samples (7%). No clear association of the genotype with the MF 
phenotype could be determined.  
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Table 22 Statistical results of 3’UTR +3111 SNP IL4R  
(FAMHAP and deFinetti) 
 MF cases n=39 Control (Mf-) n=42  
Genotype frequency
1 (%) f_al G2 frequency1 (%) f_al G2 P ATT3 
G/G 26 (66) 0.83 18 (42) 0.68 0.0145 
G/A 13 (33) +/-0.038 21 (50) +/-0.047  
A/A 0 (0)  3 (7)   
F (inbreeding) 4 -0.20  -0.14   
P (Pearson 1df) 5 0.21  0.34   
1 Genotype frequency  
2 Frequency of allele G (FAMHAP) 
3 Armitage's trend test (FAMHAP) 
4 Inbreeding coefficient, deviation from HWE (deFinetti) 
5 Pearson’s goodness-of-fit chi-square (degree of freedom=1) (deFinetti) 
 
3.7.3 Single Marker analysis for IL-18 
 
Two polymorphisms in the IL-18 gene were compared between Mf positive 
patients (Mf phenotype, no LE) and patients with LE pathology. 
The HWE statistics showed that both SNPs were in HWE as deviation of 
HWE was not significant (Table 23 and 24). 
For the two IL-18 promoter SNPs, a single-marker analysis using the 
FAMHAP program was done as described in 3.7.2. For SNP IL-18 -137, two 
samples in the control group failed the sequencing procedure, leaving 39 
cases and 81 control samples for the association analysis. In the cases 
group, 92% (n=36) carried the ancestral G/G genotype, whereas only 
75% (n=61) in the control group had this genotype. The heterozygous 
state was more frequent in the control group with 25% (n=20) carrying 
G/C, whereas only 8% (n=3) of the cases had this genotype. The 
genotype C/C was seen in neither of the groups. A significant difference of 
the IL-18 -137 genotypes were found between cases and controls using 
the ATT (P=0.0267) (Table 23) with Odds Ratio for the G-allele being 3.32 
(CI: 1.01-12.23).  
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Table 23 Statistical results of the IL-18 -137 SNP 
 LE cases n=39 Control (Mf+) n=81  
Genotype frequency1 (%) f_al G2 frequency1 (%) f_al G2 P ATT3 
G/G 36 (92) 0.96 61 (75) 0.88 0.0267 
G/C 3 (8) +/-0.021 20 (25) +/-0.024  
C/C 0 (0)  0 (0)   
F (inbreeding) 4 -0.04  -0.05   
P (Pearson 1df) 5 0.80  0.74   
1 Genotype frequency  
2 Frequency of allele G (FAMHAP) 
3 Armitage's trend test (FAMHAP) 
4 Inbreeding coefficient, deviation from HWE (deFinetti) 
5 Pearson’s goodness-of-fit chi-square (degree of freedom=1) (deFinetti) 
 
Additionally the IL-18 -607 SNP was analyzed for association to LE 
pathology. Of the 122 patients, one case and one control sample failed the 
sequencing procedure, leaving 38 case and 82 control samples. In the 
case group, 71% (n=27) carried the G/G genotype, 21% (n=8) were 
heterozygous G/T and 8% (n=3) were T/T. In the control group, 46% 
(n=38) carried the G/G or the G/T genotype while 7% (n=6) were 
homozygous T/T (Table 24). The ancestral allele of the IL-18 -607 SNP is 
the T allele. No significant association of the IL-18 promoter with LE was 
found, although the second SNP showed a trend to association (P=0.051) 
with Odds Ratio for the G-allele being 1.94 (0.995-3.79). 
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Table 24 Statistical results of the IL-18 -607 SNP 
 LE cases n=38 Control (MF+) n=82  
Genotype frequency1 (%) f_al G2 frequency1 (%) f_al G2 P ATT3 
G/G 27 (71) 0.82 38 (46) 0.70 0.0515 
G/T 8 (21) +/-0.051 38 (46) +/- 0.034  
T/T 3 (8)  6 (7)   
F (inbreeding) 4 0.299  -0.05 -0.093  
P (Pearson 1df) 5 0.064  0.74 0.398  
1 Genotype frequency  
2 Frequency of allele G (FAMHAP) 
3 Armitage's trend test (FAMHAP) 
4 Inbreeding coefficient, deviation from HWE (deFinetti) 
5 Pearson’s goodness-of-fit chi-square (degree of freedom=1) (deFinetti) 
 
3.7.4 Haplotype analysis IL-4R 
 
To assess whether the observed associations to Mf pathology were 
attributable to the IL50Val polymorphism alone or together with the 
+3111 SNP in a haplotype, a haplotype frequency estimation with the 
FAMHAP software was done. Single haplotype frequencies were estimated 
performing a likelihood ratio test (X2, 1df). To get a corrected P-value an 
Omnibus statistic with 200,000 simulations was done (Table 25). All four 
possible haplotypes were present in the groups of Mf cases and controls, 
where the Ile50Val SNP is analyzed in the first and the +3111 SNP in the 
second position. Haplotype A G was less common in both groups, whereas 
haplotype G A was equally distributed between cases and controls. 
Haplotype with A A was significantly less frequent in Mf cases (P=0.0145), 
whereas haplotype G G was significantly dominant in Mf cases 
(P=0.0378). Allele G in the IL50Val SNP, coding for valine in conjunction 
with allele G in the 3’UTR region shows a frequent haplotype in Mf cases, 
whereas the controls carry the A A genotype more frequently. The 
corrected P-value analyzed with the omnibus statistic which corrects for 
multiple testing effects, remained highly significant (P = 0.026), which 
strengthens the results of the single haplotypes. 
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Table 25 Haplotype analysis IL-4R using FAMHAP 
Haplotype Frequency   
P-value  X2 1  21 Cases controls 
A  G 0.032 0.031  
A  A 0.131 0.289 0.0145 
G  G 0.610 0.444 0.0378 
G  A 0.225 0.233  
Corrected P=0.026 
1At position 1 is SNP Ile50Val (rs1805010) and at position 2 is SNP +3111 (rs1049631). 
 
3.7.5 Haplotype analysis IL-18 
 
The haplotype analysis to find an association of the three possible 
haplotypes in the cases and controls with LE while simultaneously 
correcting the data for multiple testing was done as described in 3.7.4. A 
significant association for haplotype G G in the cases was seen, with an 
uncorrected P=0.036 that remained significant after correction for multiple 
testing (P=0.043). The haplotype, where SNP -137 has G  and -607 has 
G, which are both associated with higher promoter activity and higher IL-
18 protein expression [101, 102] was significantly more frequent in 
patients with LE pathology, whereas the haplotype C T, responsible for 
lower IL-18 levels, had a significantly lower frequency in the cases (Table 
26). 
 
Table 26 Haplotype analysis IL-18 using FAMHAP 
Haplotype Frequency   
1  2 cases Controls P value X2 
G  G 0.811 0.691 0.036 
G  T 0.148 0.183  
C  T 0.039 0.125 0.022 
Corrected P=0.043 
At position 1 is SNP -137 (rs187238) and at position 2 is SNP -607 (rs1946518). 
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4. Discussion 
 
Two of the major filarial infections, onchocerciasis and LF, affect >150 
million people. More than 1 billion people are living in LF endemic areas 
and >1 million people live in O. volvulus endemic areas and therefore are 
at risk of infection [2, 5]. Public health programs to control these 
infections have existed for years and have evolved from activities driven 
by the WHO into global programs with public-private partnerships. 
Currently, these programs use yearly mass application of drugs that 
mainly kill Mf with the aim to prevent uptake by transmitting insect 
vectors and thus, to block transmission and reduce infections to such 
levels that in 15-30 years from their beginning, the diseases will no longer 
pose a public health problem. 
It has been known for more than 35 years that filarial nematodes contain  
endosymbiotic bacteria of the genus Wolbachia of the order Rickettsiales 
[149]. These endosymbiotic bacteria are found in the hypodermis of male 
and female worms, ovaries, oocytes, embryos and all developing larval 
stages [150]. As in many animal filarial species, these endobacteria are 
present in human filariae including W. bancrofti, Brugia species and O. 
volvulus. The principle of anti-wolbachial chemotherapy of filariasis is 
based on earlier findings in animal models as well as in human 
onchocerciasis and LF that depletion resulting in a more than tenfold 
reduction of the Wolbachia endobacteria in adult female worms, precedes 
female worm sterility [41, 120] and worm death [42, 43, 45]. The 
discovery of the essential role of Wolbachia in worm fertility and survival 
has resulted in the development of an antifilarial chemotherapy with 
doxycycline, which depletes Wolbachia from the worms and leads to long-
term worm sterility [44, 47] and macrofilaricidal activity in bovine 
onchocerciasis [151] and human LF and onchocerciasis [42, 49]. 
PCR based assays have become the preferred methods for the diagnosis 
of many parasitic infections in diagnostic laboratories [67]. In recent 
years, real-time PCR has increasingly replaced C-PCR having the potential 
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to be used as high-throughput diagnostic tool for the screening of DNA 
extracted from blood and tissue. To improve diagnostic methods beside 
microscopic and histological analysis in filarial infections with O. volvulus, 
W. bancrofti and Brugia malayi, several real-time PCRs were established 
to: 1) monitor Wolbachia depletion in studies with humans looking at the 
efficacy of different dosages and treatment times for doxycycline and 
alternative anti-wolbachial drugs, 2) analyse the effect of Wolbachia 
depletion by doxycycline on larval development in the insect vector and 3) 
establish a more sensitive method of identifying amicrofilaremic Brugian 
infections. To these, the Wolbachia ftsZ single copy gene and the Brugia 
malayi HhaI gene were quantified by real-time PCR. 
The second arm of the thesis project was a genetic association study in LF 
patients. Studies in humans have shown that susceptibility to infection, 
parasite load and lymphatic pathology cluster in families but only a few 
studies have looked for genes associated with LF. In total 30 SNPs were 
analyzed and genotypes were compared between LF patients with MF or 
LE phenotypes. Two SNPs of the IL-18 gene and two SNPs of the IL-4R 
gene showed an association to LF phenotypes in a group of patients from 
Indonesia infected with B. timori. 
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Quantitative PCR 
 
4.1 Onchocerciasis 
 
4.1.1 Drug studies 
 
Drug study with doxycycline 200 mg/day 4 and 6 weeks 
To monitor the success of antibiotic treatment on Wolbachia depletion in 
O. volvulus infections, a real time qPCR for the O. volvulus Wolbachia ftsZ 
gene was established. The PCR was very sensitive with a detection limit of 
30 ftsZ copies/µl. The use of PCR was an advanced monitoring tool beside 
microscopic and histological analyses. 
One aim of the study was to define the minimum regimen of antibiotic 
treatment needed to achieve Wolbachia depletion and complete 
sterilization of adult female worms, leading to a reduction of skin Mf over 
a longer period to decrease the transmission potential. It was previously 
shown that a 6-week administration of 100 mg/day in onchocerciasis 
patients led to a depletion of Wolbachia from adult worms [41]. Two and 
three weeks of doxycycline treatment were not sufficient in previous 
studies (unpublished data). Assessment of a macrofilaricidal activity was a 
second objective. 
To achieve the first objective, we undertook a placebo-controlled, 
randomized study with 200 mg/day of doxycycline, administered for 4 and 
6 weeks, to onchocerciasis patients. The PCR results confirmed almost a 
tenfold depletion of Wolbachia with the expected interruption of 
embryogenesis that led to a cessation of production of new Mf at 20 and 
27 months after the onset of treatment. Histology results also revealed a 
macrofilaricidal activity of more than 60% in the 6-week treatment arm at 
these points of time. After subtraction of those worms that had been 
newly acquired in the interval between doxycycline treatment and the 20-
27 months follow-up analysis and thus had not been treated, the 
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macrofilaricidal rate would have been approximately 70% after 
substracting new infections. This was confirmed recently from our group, 
reanalysing the data of doxycycline treatment on onchocerciasis patients 
[146].  
The sustained absence of embryogenesis, of skin Mf and the 
macrofilaricidal activity was greater after 6 weeks compared to 4 weeks of 
doxycycline administration.  
 
Drug study with doxycycline 100 mg/day 5 weeks 
 
To analyse the efficacy of doxycycline alone without administration of IVM 
an open trail with 5 weeks treatment of doxycycline 100 mg/day in 
onchocerciasis patients was undertaken. In addition qPCR analysis of 
Wolbachia depletion, assessment of a macrofilaricidal activity and long-
term sterilizing effect were made.  
In previous studies, a 6-week course of doxycycline 100 mg/day resulted 
in long-term (>24 months) sterilization of female worms and an absence 
of skin Mf but no macrofilaricidal effect could be seen [41, 44, 47]. 
Three new findings were observed with the 5 weeks doxycycline 
treatment: (1) Wolbachia depletion and interruption of embryogenesis 
was achieved after reduction of the treatment duration from 6 to 5 weeks 
at 100 mg/day of doxycycline. (2) Wolbachia depletion and sterility were 
observed for a longer time of 21 and 27 months than previously seen. (3) 
this Doxycycline regime showed a macrofilaricidal activity [46]. 
At 21 months after treatment, the ftsZ/β-actin ratio was decreased almost 
10 fold. At 27 months after treatment, the difference to the control group 
was not significant anymore, even if the median ratio was as low as at 
month 21. Ongoing transmission leads to the acquisition of new worms 
after the administration of doxycycline, some of which in our study have 
already become fertile during the 21-27 month observation period. This 
was confirmed be reanalysis of the data by our group [146]. The female 
worms harbouring many Wolbachia showed the characteristics of young 
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worms that had been newly acquired after the end of doxycycline 
treatment. These newly acquired worms also produce new Mf that are 
detected by PCR of the skin biopsies.  
 
Drug study with azithromycin  
 
Azithromycin has good activity against intracellular bacteria such as 
Chlamydia spp. (which are related to Wolbachia) and Mycoplasma spp.. It 
was administered to onchocerciasis patients in different dosages for 6 
weeks with the aim to study effects of azithromycin on the Wolbachia of 
O.volvulus and on Mf production. The advantage for including 
azithromycin into anti-wolbachial chemotherapies is that it can be given to 
children, thus closing one of the gaps left by doxycycline. In addition, the 
weekly regimen of 1,200 mg of azithromycin that is used in HIV-infected 
individuals as prophylaxis against infections with atypical mycobacteria 
[52], azithromycin would potentially provide an easier application in areas 
with rural health standards.  
As in previous studies with doxycycline, real-time PCR was used to 
monitor the effects of the antibiotic treatment on the Wolbachia depletion. 
The bacterial ftsZ gene was quantified after the azithromycin treatment 
and compared to the control group. 
Unfortunally, the weekly regimen showed no efficacy for Wolbachia 
depletion analyzed by qPCR, confirming the histological analysis. A recent 
study with treatment of onchocerciasis patients for five days with 
rifampicin or azithromycin or with both drugs showed that neither of this 
regimens caused depletion of Wolbachia, a reduction of Mf in the skin nor 
degeneration of adult worms 9 months after treatment [152]. The authors 
concluded that short courses with these antibiotics will not clear Wolbachia 
from O. volvulus. Our data suggest that longer regimens with 
azithromycin alone were also not effective. Histological data found that 
there was a significant reduction in the proportion of worms with many 
bacteria (―many bacteria‖ was defined as the presence of worms with 
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many bacteria in several sections of the same worms with at least one 
section showing more than 50 and usually more than 100 bacteria) 12 
months after administration of 250 mg/day azithromycin [119], 
suggesting an effect of the drug on some worms.  However, 53% of living 
female worms still displayed normal embryogenesis, and 68% of nodules 
from the group at 12 months had Mf in the nodular tissue. These 
proportions were similar to those of the untreated group, the 6-months 
follow up and the 1,200 mg/week regimen.  
The PCR results additionally showed that a Wolbachia reduction could not 
be achieved with daily or weekly treatment. The reduction of the 
Wolbachia content at 12 months seen with histology could not be 
confirmed by PCR. This is may due to remaining DNA of degenerating 
bacteria which were still detectable with PCR but not seen in histology 
examination of the worms. In conclusion, a 6-week treatment with 250 
mg/day or 1,200 mg/week with azithromycin alone is not suitable for 
treatment of human onchocerciasis. It may be worthwhile however to 
investigate the Wolbachia-reducing capacity of azithromycin in 
combination therapies together with other anti-wolbachia drugs. 
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Summary drug studies in Onchocerciasis 
 
In summary, anti-wolbachial chemotherapy of human onchocerciasis with 
doxycycline can be orally applied for special indications to sterilize the 
female filariae and reduce the adult worm load. It cannot replace IVM for 
mass treatment in areas with ongoing transmission. Its use in community 
based control is compromised by the logistics of the length of treatment 
and contraindications in children and pregnant women. 
Even a 4- and 5-week treatment with doxycycline is too long for use as 
MDA and the appearance of newly acquired worms after doxycycline in a 
focus with ongoing transmission show clearly that IVM remains the drug of 
choice for the areas which are currently covered by the African 
Programme for Onchocerciasis control [22].  
However, a recent report on community-directed delivery of doxycycline 
for the treatment of onchocerciasis indicated that a successful delivery of 
doxycycline for six weeks is practicable. The therapeutic coverage and the 
compliance treatment rate achieved in this study coupled to the known 
efficiency of doxycycline showed that mass administration may be used in 
selected problem areas (i.e. loiasis co-endemic areas) as an additional 
measure to control onchocerciasis [153]. 
In addition, the new chemotherapeutic principle is beneficial to the 
treatment of individual patients, who have left transmission areas and 
thus can achieve a strong reduction of the adult worm load and a 
clearance of Mf. The new regimen may also be considered in areas where 
there has been evidence for a sub-optimal performance of IVM. Worm 
populations that might have acquired some degree of resistance may thus 
be eliminated with an existing drug to prevent resistance from further 
spreading. Doxycycline without IVM may also be considered for treatment 
in areas with co-endemicity of onchocerciasis and loiasis [154]. 
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4.1.2 Vector monitoring 
 
Retarded O. volvulus L1 to L3 larval development in the Simulium 
damnosum vector after anti-wolbachial treatment of the human host 
 
In previous studies much work has been done showing the requirement of 
Wolbachia for oogenesis, embryogenesis and adult worm survival in 
infections with the filarial parasite O. volvulus [41, 44]. Other studies 
have analyzed the effects of tetracycline on larval development in the 
mammalian host. It was seen that tetracycline treatment in a mouse 
model with L. sigmodontis, leads to significant growth retardation in 
worms [38] when administered concomitantly with the start of infection. 
Oral treatment with tetracycline inhibited Brugia pahangi and Brugia 
malayi development from L3 to adult worms in jirds and gerbils [155-
158]. Different to animal models, little is known in human infection about 
the effects of an antibiotic treatment of the mammalian host on the larval 
development in the insect vector. Therefore the focus of this study was to 
analyse the biology of the Wolbachia-O. volvulus symbiosis regarding the 
effect of Wolbachia depletion on larval development in the insect vector. It 
was investigated whether Mf from onchocerciasis patients that had been 
treated with doxycycline, and thus had reduced or absent Wolbachia 
levels, could still develop into the infective L3 in the Simulium vector. 
Simulium flies were allowed to bite onchocerciasis volunteers and were 
then captured and raised in an insectarium. The capture site was selected 
based on the results of dissection of wild Simulium flies to determine the 
natural parous, infection and infective rates. The river site picked to allow 
volunteers to be bitten by blackflies had very few infected flies (infection 
rate of 0.001%). Therefore, all flies captured on the volunteers after the 
bloodmeal should only contain Mf from the volunteers. 
After 7 days, the Simuliae were dissected and the L3, L1 and L2 larvae 
counted. 
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Our results showed that Mf treated with doxycycline, and therefore 
depleted of their Wolbachia, developed into L3 at a considerable lower 
rate than Mf from placebo treated patients during the observation period. 
This was most apparent as a decrease of L3 with a corresponding increase 
of L1 and L2 was seen in the doxycycline group at 3, 4 and 5 months 
post-treatment. Whether the few remaining L3 with low numbers of 
Wolbachia might be able to establish an infection in humans remains an 
open question that is technically and ethically impossible to answer for O. 
volvulus infections. 
Although not significant, within the placebo group the number of L3 larvae 
recovered from the Simulium decreased over time post-treatment. One 
explanation for this could be the drop in temperature (from 28°C to 24°C) 
in the area at these time points. It is likely that due to seasonal 
differences, the capacity of the Simuliae to support the infective L3 is 
reduced at these time points. However, this would need to be confirmed in 
further experiments. Nevertheless, there is a significant difference in the 
L3 reduction observed between the doxycycline and the placebo treated 
volunteers. Inhibition of larval development after antibiotic treatment has 
been observed in several other studies. In a murine model with L. 
sigmodontis, significantly fewer L3 developed in the intermediate host if 
Mf were depleted of their Wolbachia endobacteria with tetracycline 
treatment [159]. Furthermore, infection of jirds with Wolbachia-depleted 
L3 resulted in the development of very few female worms, while male 
worm numbers were unchanged. The few female worms that were able to 
develop from Wolbachia-depleted Mf had endobacteria levels equivalent to 
control worms. It was postulated that these worms developed from Mf 
with a Wolbachia threshold level at or above the minimum that allows for 
successful development of the larvae, and that different thresholds appear 
to exist for male and female worms. 
For the current study, equal conclusions for the L3 that had successfully 
developed can be drawn. The L3 apparently resulted from L2 containing 
the minimum threshold of Wolbachia endosymbionts needed for 
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development into L3. To prove the dependence of larval development on 
Wolbachia, the study included quantitative analysis of the endobacterial 
content in the different larval stages. The depletion of the endobacteria 
was verified by a quantitative PCR assay for the Wolbachia ftsZ gene, 
which allowed for quantification of fewer than 30 DNA copies (30 
Wolbachia) in one reaction. The PCR results showed a clear reduction of 
Wolbachia ftsZ in the Mf after one month of antibiotic treatment (52% 
compared to placebo), with Mf from fewer than 50% of volunteers having 
a detectable ftsZ signal at 2, 3, 4 and 5 months post-treatment. This was 
concomitant with a clear reduction of the ftsZ/β-actin ratio in larval 
samples from the blackfly vector in the doxycycline group, with many 
samples being ftsZ negative. As there were still remaining L3 with a 
positive ftsZ signal in the PCR, we assume that the depletion of Wolbachia 
was suboptimal and therefore resulted in a slower depletion of the 
endobacteria. It is also possible that Wolbachia DNA from 
damaged/degraded larvae is detected with the PCR. It was previously 
shown in a in-vitro study with Wolbachia infected insect cells, that 
Wolbachia tend to further decrease even after antibiotic withdrawal [160] 
These results were consistent with in vivo studies with the O.volvulus 
related parasite O. ochengi in cattle [123]. This could explain why there is 
no total decline of Wolbachia as measured with the ftsZ gene directly after 
the treatment (1 month post-treatment). Due to the small sample size a 
statistical test for significant differences between the two groups was not 
possible. However, these results show that Wolbachia are not only 
essential for O. volvulus oogenesis and embryogenesis, but they are also 
needed for proper development of the larvae in the insect vector. 
A couple of studies considered that the antibiotic treatment might directly 
affect the larval development independently of the loss of endobacteria 
[156, 158]. In the current study the larvae were not exposed to 
doxycycline while in the insect vector since the treatment occurred before 
the blackflies had fed on the infected volunteers. Because doxycycline 
rapidly blocks embryogenesis by Wolbachia depletion [114] , the Mf taken 
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up by the flies during the blood meal should only be those present at the 
time of doxycycline treatment. From this it can be concluded that 
Wolbachia depletion alone causes the impairment of larval development 
and is not a direct effect of the antibiotic on the larvae. Because L2 larvae 
were able to develope in the flies, we also conclude that many of the Mf 
from the doxycycline patients were still alive, indicating that Mf do not rely 
on their endosymbionts, but still need a threshold number of Wolbachia in 
order to further develop in the insect host. 
The possible role of Wolbachia during filarial development and the 
underlying molecular mechanisms are still unknown. The bacteria might 
function as a source of heme for enzymes participating in the biosynthetic 
pathways of hormones or other metabolites needed for moulting [40, 
161]. It is known that in Dirofilaria immitis and B. pahangi, moulting from 
L3 to L4 in vitro is dependent on heme requiring hormones like ecdysone 
[162, 163]. The annotated genome of B. malayi lacks the genes for heme 
synthesis but could be found in the Wolbachia genome [36, 40]. Therefore 
Wolbachia could serve as a source of heme and benefit the parasite larval 
development. 
This is the first study analysing the effects of antibiotic treatment in 
human onchocerciasis on larval development in the insect vector. The 
results clearly show that depletion of Wolbachia not only affects the larval 
stages and adult worms in the mammalian host, it has also a negative 
effect on larval development in blackflies. These findings have 
epidemiological implications. The decrease in L3 production, even though 
it is not 100%, could reduce the transmission potential of black flies 
following treatment of communities with doxycycline to control 
onchocerciasis. Thus anti-wolbachial therapy for filarial infections would 
have an additive effect of interrupting transmission by 1) blocking 
embryogenesis 2) macrofilaricidal activity and 3) reduction of  the number 
of L3 that can be transmitted by black flies that have fed on infected 
persons before the Mf have been cleared from the skin.  
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As mentioned earlier in the discussion (4.1.1) a report on community-
directed delivery of doxycycline for the treatment of onchocerciasis is 
achievable and showed that mass administration may be used in selected 
problem areas such as in areas coendemic for loiasis to control 
onchocerciasis [153]. 
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4.2 Lymphatic filariasis 
 
4.2.1 Drug studies 
 
Drug study with rifampicin and/or doxycycline in W. bancrofti infection 
 
Lymphatic filariasis (LF) is a common cause of morbidity in humans, and 
of the presently used anti-filarial drugs to combat it, only DEC (which is 
not used in African countries co-endemic for onchocerciasis) has moderate 
macrofilaricidal activity, whose mode of action is not fully understood [8, 
164]. Previous trials with doxycycline targeting the Wolbachia 
endobacetria indicated that either a 4- or 6-week course of 200 mg/day 
leads to gradual and sustained loss of Mf from host blood and has strong 
macrofilaricidal activity in infections with W. bancrofti [42, 43, 51]. 
However, the previously published doxycycline regimens are long, and 
therefore a shorter regimen is desirable to complement classical anti-
filarial drugs [154]. Rifampicin is a safe drug that can be given to children 
and has already shown good activity against Wolbachia in experimental 
trials [53, 54]. In the current study, a combination of doxycycline and 
rifampicin was analyzed in a 2-week treatment and compared to 4-week 
treatment with doxycycline alone in W. bancrofti infected individuals.  
The depletion of endobacteria was analyzed using a real-time PCR assay 
for the ftsZ gene of the Wolbachia in W. bancrofti. In the group treated for 
2 weeks with doxycycline+rifampicin, a 86% Wolbachia depletion and a 
moderate macrofilaricidal effect (50%) indicated by the loss of worm nests 
(FDS) could be observed. In contrast, in the placebo patients the worm 
nests remained stable throughout the follow up examinations. 
A very low microfilaremia at 12 and 18 months after 
doxycycline+rifampicin treatment confirmed the effect of the combined 
antibiotics. The present trial confirmed a previous report that a 4-weeks 
doxycycline treatment results in more than 80% macrofilaricidal effect 
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[165]. The second and novel result of this study was that the combination 
of rifampicin with doxycycline had an anti-wolbachial effect on W. 
bancrofti in humans and this effect occured with a shorter (2 weeks) 
course of treatment. It is of interest to note that even though 3 weeks 
doxycycline alone in a previous trial had 86% Wolbachia depletion [50], it 
did not show a macrofilaricidal effect. In the group treated for 2 weeks 
with the combination of rifampicin+doxycycline with a similar degree of 
Wolbachia depletion (86%) a moderate macrofilaricidal effect was shown. 
The reason for this difference may be that, in addition to its anti-
wolbachial effect, rifampicin may have some anti-filarial activity as known 
in animal models [54, 166, 167]. Hence, a longer regime such as 3 weeks 
may show a stronger macrofilaricidal effect. The advantage of a 
macrofilaricidal drug is that it targets the adult worms that are the 
inducers of lymphatic pathology and thus can bring direct relief to 
individual patients that seek treatment, e.g. in outpatient clinics, without 
having to rely on the indirect means of reduction of infection pressure due 
to transmission control by microfilaricidal drugs. However, the previously 
published doxycycline regimens are long, and therefore a shorter regimen 
is desirable to complement classical anti-filarial drugs [154]. 
This calls for a larger study to test other regimes of longer duration with 
rifampicin in LF. A current field study of our group with different regimens 
of doxycycline and rifampicin will determine whether a longer duration will 
have a better macrofilaricidal effect or not. Such a regimen with stronger 
macrofilaricidal effect, especially with rifampicin alone will be beneficial to 
infected children in endemic areas who cannot take doxycycline but can 
take rifampicin. 
It is likely that 2 weeks doxycycline+rifampicin could have stronger 
macrofilaricidal activity than the 50% observed in this study when 
patients are observed for a longer period. However, due to high 
transmission rate in this area, longer follow-ups are not possible because 
of re-infection. Notwithstanding, the study showed that 2 weeks 
doxycycline+rifampicin had a macrofilaricidal effect and is encouraging in 
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the sense that it serves as further proof that anti-wolbachial therapy as a 
treatment against LF may be possible with a shorter regimen if anti-
wolbachial drugs are combined. The results of the combination of 3 weeks 
doxycycline and rifampicin in an ongoing trial will provide more 
information.  
 
4.2.2 Brugia malayi Diagnostic PCR 
 
Detection of HhaI gene in infection with B. malayi by real-time PCR 
 
To date, LF has been mainly diagnosed by direct microscopic 
demonstration of Mf in peripheral night blood of infected people. However, 
this method does not detect those individuals who have adult worm 
infection but are amicrofilaremic or have a pre-patent infection and are 
therefore cryptic infections. For W. bancrofti infections, assessment by the 
determination of antigenaemia using ICT® or TropBio ELISA test kit is 
available to detect amicrofilaremic infections, which in addition offers the 
convenience of ―any-time-of-day testing‖ [168]. It could be shown in 
bancroftian filariasis, that approximately twice as many individuals are 
CFA positive compared with being microfilaremic, so that a proportion 
equal to the Mf positives harbours cryptic infections. The use of USG is an 
additional tool to diagnose infections in LF because of W. bancrofti and is 
able to detect adult filarial worms by their typical movement pattern 
(FDS) [6]. The worm nests are stable over time in the scrotal area of men 
[7, 49]. In brugian filariasis, which accounts for 10% of the 120 million 
infections of LF worldwide, no antigen (CFA) test is available and early 
attempts to detect adult filariae with USG examinations failed [169]. In a 
study by our group validating USG for detection of brugian filariasis it was 
possible to detect adult B. malayi in rodents [170] and worm nests in 
single human cases, but the worm nests were not stable, i.e. they were 
not visible for longer than 10-12 min [9]. It is assumed that the adult B. 
malayi change their location within the lymphatic vessels of the human 
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body. Thus, the use of USG is limited for the monitoring of brugian 
infections.  
Several recombinant B. malayi antigens have been used in ELISAs or 
rapid-format assays to detect filarial-specific IgG4 antibodies [168]. A 
disadvantage of antibody detection is that it is an indirect diagnostic 
approach which relies on the host’s immune response. Since the 
antibodies persist even after the worms have died and have been cleared 
from the host, a positive test results do not necessarily indicate current 
infection. Nevertheless, anti-filarial IgG4 antibodies have been correlated 
with the presence of Mf in the peripheral blood as the antibody levels 
decline rapidly after microfilaricidal treatment [63]. Several studies tested 
the sensitivity of SWA-ELISA and BmR1-ELISA vs. BmR1 dipstick assay 
[124, 171]. The ELISA format using SWA showed higher sensitivity than 
the BmR1 dipstick assay, whereas the BmR1 ELISA was less sensitive 
compared to BmR1 dipstick test. It was suggested that due to the mixture 
of filarial antigens used in SWA, which may recognise antibodies produced 
by exposed but not infected individuals, and/or by individuals who have 
cleared the infection, this ELISA detects more IgG4 positive individuals. 
The combined results of two multicenter evaluations of the BmR1 dipstick 
test using B. malayi sera from three endemic countries and using sera 
from individuals with non-lymphatic filarial infections revealed a sensitivity 
of 97% and a specificity of 99% [172]. The results are based on Mf 
positive samples, whereas the number of infected but Mf negative 
individuals cannot be evaluated with the current diagnostic procedures. In 
our study using quantitative PCR, we observed similar results for the two 
IgG4 test, as the SWA-ELISA matched to PCR in 50.1%, whereas the 
BmR1 dipstick results only matched in 33.5%. Notably, the SWA-ELISA 
was unable to get a positive result for all Mf positive individuals (2 of 19 
individuals were negative for SWA-ELISA), whereas all 19 Mf positive 
samples gave a postivie BmR1 dipstick result. This is in agreement with 
the suggestion that the BmR1 format is more senstive for active fiarial 
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infections, whereas the SWA antigen mixture also detects IgG4 antibodies 
of cleared infections or exposed but not infected individuals. 
Filariasis experts have requested the development of tests that can detect 
infection in individuals with ultra low Mf densities or cryptic infections 
[173]. To meet this request the HhaI QuantiTect® PCR, previously 
developed by Rao et al. [128], was optimized and validated with a B. 
malayi animal model and a transmigrant population in Indonesia. In the 
current experiments, the QuantiTect® PCR assay was sensitive at 
detecting Brugia DNA in pre-patent amicrofilaremic animals, Mf positive 
patients from Central Sulawesi and amicrofilaremic patients from South 
Sulawesi.  
The 320-bp HhaI tandem repeat sequence of B. malayi has been used as 
a target for B. malayi PCR assays for many years [174]. Rao et al. found 
that detection of the Brugia HhaI repeat was as sensitive as microscopic 
detection of Mf. Additionally the real-time PCR assay showed higher 
sensitivity compared to conventional PCR and TaqMan PCR assays and 
detected DNA of nocturnally periodic B. malayi in day blood samples. This 
represented a significant improvement over previously available diagnostic 
methods in brugian filariasis. The HhaI repeat is specific for brugian 
filariasis and was not detected in W. bancrofti infections, which is also 
endemic in South East Asia.  
To get a more detailed view about the sensitivity of the HhaI assay, 
particularly in amicrofilaremic infections, a large number of individuals 
that had moved from a non endemic area to a B. malayi endemic area 
were analyzed. Particularly in the group of individuals who were in the 
endemic area less than three years, the results showed a very high HhaI  
positive rate (up to 87%), whereas in the first months, none of these 
individuals were IgG4 positive. After four years, HhaI copy numbers 
increased concomitant with more individuals tested IgG4 positive and 
reached similar levels of LLR. 
The uniform detection rate for HhaI (>80%) in many transmigrants in 
their first three years of residence might be explained by high exposure to 
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infective larvae but not yet adult worms, as indicated by the low HhaI 
copy numbers detected (72% had <53 HhaI copies/µl). This could explain 
the discrepancy of PCR and IgG4 results in the first years of living in an 
endemic area. The parasite burden is probably not high enough to 
produce detectable IgG4 antibodies, whereas PCR is able to detect 
parasite DNA including individuals that are exposed to infective larvae. 
Notably there were individuals with high HhaI copies/μl who were IgG4 
negative. Based on serology they would have been diagnosed as Brugia 
negative even though it is likely they had active infections. Conversely, 
however, there were also 19 IgG4 positive individuals that were diagnosed 
as PCR-negative, indicating previous but not current exposure to filarial 
worms or larvae.  
The PCR results showed that HhaI copies/µl increased with length of time 
in the area and probably indicate active infections. For monitoring Brugia 
infections using day samples a threshold associated with active infection 
was set to >53 HhaI copies/µl using 10 µl of plasma DNA with the 
optimized QuantiTect® Virus NR Kit protocol, based on ROC-curve 
analysis. This analysis predicts 80% sensitivity for detecting an active 
infection in amicrofilaremic individuals with a corresponding false positive 
rate of 20% (―1-Specifity‖). 
Two individuals (children) resident in the area <1 month had >1000 HhaI 
copies/µl. Repeated PCR runs and sequencing verified the PCR product 
and HhaI copy numbers. These two outliers may have been highly 
exposed to infective larvae or they may have been infected by larvae of B. 
timori or B. malayi prior to settlement in the area.  
Introduction of the CFA test for W. bancrofti infections showed that 50% 
of the population in an endemic area had a latent infection. In our study 
with quantitative real-time PCR we observed a similar level of latent 
infections with B. malayi not detected by IgG4 serology or microscopic 
analysis. Due to possible development of severe LF pathology such as LE, 
the ability to determine the status of infection, especially in 
amicrofilaremic patients, as early as possible could lead to prevention of 
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disease progression in individuals of endemic areas. In the absence of an 
antigen test for brugian infections the optimized B. malayi HhaI PCR can 
be used as a surrogate to identify infected, Mf negative individuals. Real-
time PCR can be used to screen human samples to identify and map areas 
of endemicity and should also be useful for assessing the success of MDA 
in the framework of the Global Program to Eliminate Lymphatic Filariasis. 
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Genetics 
 
4.3 Genetic associations in brugian filariasis analyzed in   
patients from Alor Island, Indonesia 
 
Host genetics can be the basis for understanding an individual’s disease 
status. One of the first reports of a specific SNP associated with the 
variations seen in filarial pathologies showed an association of the 
Arg110Gln variant in the IL-13 gene and severe skin pathology in 
onchocerciasis [83]. Previous studies have shown the association between 
polymorphisms in various host genes [e.g., human leucocyte antigen 
(HLA), Chitotriosidase (CHIT1), mannose-binding lectin (MBL), vascular 
endothelial growth factor A (VEGF-A) and Toll-like receptor 2 (TLR2)] and 
susceptibility as well as clinical types of LF [84-90]. Additionally, a variant 
in the transforming growth factor-beta 1 (TGF-β-1) gene in LF patients was 
found to be associated with the lack of Mf and differential Mf loads in 
blood [91]. 
The objective of the present study was to analyse 30 SNPs for association 
to LF pheotypes. After analysing the genotyping results with FamHap, two 
SNPs in the IL-18 gene and two SNPs in the IL-4R gene showed 
association in lymphatic filariasis patients.  
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4.3.1 IL-18 
 
Both IL-18 SNPs are known to be associated with up-regulation of IL-18 
levels in several inflammatory diseases. These include development of 
atopic dermatitis-like inflammatory skin lesions [175] and collagen-
induced inflammatory arthritis [176] in mice; Crohn’s disease [177, 178], 
atherosclerosis [179], rheumatoid arthritis [97, 180], Systemic Lupus 
Erythematosus [102, 181, 182] and sarcoidosis [103] in humans. 
IL-18, earlier known as IFN-γ and TNF-α inducing factor, is a pro-
inflammatory cytokine which plays an important role in the development 
of both Th1 and Th2 cells. The major source is macrophages, although 
many other cell types are also capable of producing IL-18. It is produced 
as an inactive precursor molecule, which is processed by caspase-1 
whereby biologically active molecules are released [183]. Its production 
and activity is regulated by caspase-1, IL-12 and nitric oxide. Although 
production of IL-18 is affected by many factors, individual differences in 
levels of this cytokine are also caused by genetic polymorphisms [101]. 
The influence of the -137 and -607 SNPs on IL-18 mRNA levels were first 
described in autoimmune diseases [101]. Higher IL-18 mRNA levels in 
multiple sclerosis (MS) patients homozygous for G at position -607 and G 
at position -137 were observed. The authors also found a correlation to 
IL-18 and IFN-γ expression in patients which carried the G variant. In the 
promoter region of the IL-18 gene, there is a cAMP response element 
(CRE) sequence near position -607. When activated by cAMP, the cAMP 
response element binding protein (CREB) binds to this region of the 
promoter to activate transcription [184]. A change from nucleotide G to 
nucleotide T disrupts the CRE sequence. Therefore, the G/G genotype 
results in higher transcription activity than the other genotype, with a 
corresponding expression of higher levels of the IL-18 protein.  
In patients with sarcoidosis, a multisystem disorder characterized by 
granulomas in lungs or lymph nodes, the G allele is significantly more 
frequent compared to controls [103]. SLE is an autoimmune disease 
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characterized by production of high titers of autoantibodies and clinical 
manifestations that include arthritis, vasculitis and nephritis. In SLE 
patients, who have elevated IL-18 levels, the frequency of genotype G/G 
at position -607 was significantly higher, whereas the heterozygous 
genotype G/T was significantly decreased [102].  
The same picture was seen the current study in patients with lymphedema 
(LE), where the homozygous G allele at position -607 was more frequent 
(71% cases, 46% controls), whereas the heterozygous G/T was less 
frequent (21%) compared to controls (46%).  
The SNP at position -137 is in an H4TF-1 nuclear factor-binding site [101]. 
It was postulated that the C allele at position -137 would alter binding of 
the H4TF-1 nuclear factor and would therefore result in lower IL-18 mRNA 
expression. In the study patient group we did not detect any LE cases 
homozygous for C, and even the heterozygous genotype was decreased in 
the cases group (8%), although HWE was not disturbed. Thus, cases were 
more frequently homozygous for the G allele (92%), which is associated 
with higher IL-18 levels. The lack of homozygous C at -137 is not novel. 
In the context of a cluster report in 2004, Cox and Patil (Perlegen Science) 
analyzed 42 samples of Chinese descent for the -137 SNP and found the 
homozygous G/G genotype in 81% of the group while 19% were 
heterozygous C/G. The C/C genotype was not detected in this analysis 
(Cluster report ss24320556; http://www.ncbi.nlm.nih.gov/).  
The pathology of LE was attributed to the death and destruction of adult 
worms within the lymphatic vessels. Clinical studies have also implicated a 
role for secondary opportunistic infections along with other cofactors in 
progression of LF pathologies. Chronic inflammation was characterized by 
recurrent attacks of acute filarial lymphangitis [75]. Asymptomatic 
microfilaremic individuals have low (suppressed) immune responses to 
parasite antigens, whereas those with pathology have inflammatory 
reactions to the parasite that respond strongly to such antigens [185]. 
With respect to lymphocyte proliferation to filarial antigens, several 
studies documented that individuals with chronic pathology have elevated 
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levels of IgE, IgG1-3 and IFN-γ [186, 187], which can all be induced by 
IL-18. Asymptomatic microfilaremic individuals produced relatively low 
levels of IgG 1-3, IgE, IFN-γ and GM-CSF. Instead they produced high 
levels of IgG4, IL-10 and TGF-β, which are associated with immuno-
suppression. The response to parasite antigens is: 1) the production of 
pro-inflammatory mediators of the immune system (Th1 cytokines) and 2) 
the elimination of the worm by a Th2 mediated response. IL-18 can 
promote both Th1 and Th2 immune responses [92, 188]. In the current 
study an association of genotypes responsible for up-regulation of IL-18 in 
individuals with chronic LE pathology was found. Thus, patients with this 
genotype may be more at risk of developing LE due to their genetic 
predisposition to produce high levels of IL-18 as part of their immune 
response.  
 
4.3.2 IL-4R 
 
IL-4 and IL-13 are two cytokines which play key roles in the development 
of Th2 cells, a hallmark of many worm infections. Both cytokines use the 
same receptor alpha chain and seem to share many physiological 
functions. Chronic human helminth infection in onchocerciasis, especially 
the rare sowda form, is characterised by a strong Th2 phenotype with very 
high IgE levels compared to the immunotolerant form (generalized 
onchocerciasis) [189, 190].  
The Arg110Gln variant of IL-13, proposed to have higher bioreactivity 
resulting in higher levels of serum IgE provided information on the 
different degrees of skin pathology seen in patients infected with O. 
volvulus [83]. Analysing the IL-13 SNP in onchocerciasis patients, it was 
seen that a variant in this SNP is a significant risk factor for the 
development of sowda and higher IgE levels were found in this group of 
patients. 
The Ile50Val SNP in the IL-4R gene is associated with different receptor 
activity and IgE levels. To test whether the Ile50Val variant promotes 
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dysregulation of IgE synthesis, Mitsuyasu et al. conducted a genetic 
association study for serum IgE levels in a Japanese population [111]. A 
significant difference in the genotype frequencies was seen between 
control and atopic subjects; Ile 50 was associated with atopic asthma and 
raised total serum IgE levels. Further experiments with mouse and human 
B-cell lines showed almost 3 times greater cell growth and expression 
under the control of the IgE promoter with the Ile 50 variant compared to 
Val 50 transfected cells (15.4-vs 5.4-fold increase, respectively).  
The C-terminal ends of the IL-4R and IL-13R subunits interact with 
tyrosine kinases of the JAK-family, leading to interaction with STAT6, 
which binds to consensus sequences in the promotors of IL-4 and IL-13 
regulated genes [107, 108]. Thus, it was also confirmed that the Ile 50 
variant augmented STAT6 activation 1.8-fold compared with the Val 50 
variant in mouse and human B-cells [111]. These data suggested that the 
Ile 50 variant significantly up-regulates the receptor response to IL-4, 
resulting in increased activation of STAT6, and hence increased cell 
proliferation and increased IgE production.  
In murine filariasis with L. sigmodontis infection it was seen that IL-4 
knockout mice have an up to 100-fold-higher and a significantly prolonged 
microfilaremia compared to wild-type BALB/c mice as well as 20 times 
more Mf in the thoracic cavity, the site of infection [106]. It confirmed 
that IL-4 is essential for Mf containment and a limiting factor on Mf 
survival, whereas the adult female fertility is enhanced and larval 
development is unaffected. Another study with IL-4 and IL-4/IL-10 
knockout mice confirmed that in the IL-4 knockout mice the worm 
recovery is increased after 42 and 65 days p.i. [105]. With mice lacking 
the IL-4R-alpha-chain (unable to respond to IL-4 or IL-13) it could be 
shown that they had the same Mf loads as IL-4-deficient mice and thus 
excluded that IL-13 could compensate for the lack of IL-4 with regard to 
Mf containment [191]. Adult worms were affected in the opposite 
direction, if the IL-4R is knocked out. Volkmann et al. and other 
experiments from Maizels et al. observed a lower recovery of adult worms 
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in IL-4R knockout mice compared with IL-4 knockout and wild-type [192]. 
It is assumed that the extremely strong induction of fibrosis (probably 
mediated by IL-13 and the IL-13R2) that these mice display also extends 
to encapsulating worm nests and thus leads to lower recovery of adult 
worms. Because of the importance of IL-4 and IL-4R as modulators of the 
immune response and their importance in limiting Mf loads in murine 
filariasis, two SNPs in the IL-4R loci were studied. 
More than 40% of the Mf patients (cases) were homozygous for the G 
allele coding for the amino acid valine at position 50 (rs 1805010). The 
ancestral allele A coding for the amino acid isoleucine is homozygous in 
only 15% of the cases, whereas in the control group, the A allele is more 
frequent (homozygous 26% and heterozygous 52%). As the isoleucine 
variant is associated with elevated receptor activity and therefore 
increased STAT6 and IgE levels, it seems likely that the valine variant 
stays for contrary effects. This would result in low IL-4 and IL-4R activity 
in Mf patients which fits to previous results mentioned above, where the 
important role of IL-4 and the IL-4R on Mf containment was described. 
The results are strengthened by a haplotype analysis with another SNP in 
the IL-4R. This SNP is positioned in the 3’UTR region (+3111 mRNA 
position) and showed no positive association in Mf patients in the single-
marker analysis. Together with the Ile50Val SNP, the haplotype G G was 
more frequent and significantly associated with Mf patients compared to 
controls.  
Patients who have elevated levels of Mf and no LE development show 
decreased IgE levels [74]. This could be due to a diminished IL-4R 
activity, as the majority of these patients in the current study did not have 
the genotype for elevated IL-4R activity and increased STAT6 and IgE 
levels. They carried the valine genotype which was thought to have a 
significantly lower IL-4R activity and therefore lower STAT6 activity and 
the resultant lower IgE production. The reduced signalling by the IL-4R 
and the decreased IgE levels would support the conclusion that more Mf 
are able to circulate in the host. 
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Summary Genetics in LF 
 
Until now, very little is known about specific SNPs and their influence in 
brugian LF. The immunological perspective of filarial disease would 
suggest that it is the character of the immune response that determines 
the host’s clinical outcome of infection. It is likely that the genetic 
background of an infected individual influences the immune response and 
therefore the disease phenotype. The results of our association analysis of 
IL-18 and IL-4R have provided further evidence for an association of 
specific SNPs in immune regulating genes with LE and microfilaremia in 
brugian filariasis. Knowledge of an individual’s genetic propensity to be 
microfilaremic could be used for individual therapy. Patients could be 
screened using an IL-4R epitope antibody to identify patients with the 50 
Val SNP who could then theoretically be treated to increase IgE levels. 
This could lead to a greater portion of the affected population being 
amicrofilaremic, which would then help to halt further spread of the 
disease. 
The results of association of IL-18 and LE pathology provides more insight 
to the genetic basis of associated immune regulators previously found to 
be correlated with the outcome of pathology in infected patients. The 
longstanding assumption of a genetic predisposition and the outcome of 
the disease were confirmed based on associated SNPs.  
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Summary 
 
In the first part of this thesis, the aim was to establish real-time qPCR 
assays to complement histological analysis by quantifying the depletion of 
Wolbachia endobacteria after several different treatment regimens with 
doxycycline alone, in combination with rifampicin, or with azithromycin in 
onchocerciasis and LF patients. This was achieved by using the bacterial 
ftsZ gene normalized to worm β-actin and was found to be a reliable 
method to monitor anti-wolbachial treatment in filarial infections. 
Wolbachia depletion after treatment with 200 mg/day doxycycline for 6 
weeks was most effective and showed macrofilaricidal activity in 
onchocerciasis. A 4-week treatment with 200 mg/day or a 5-week 
treatment with 100 mg/day can be used if interruption of embryogenesis 
is the desired outcome in onchocerciasis infections. Although it must be 
noted that a 49% macrofilaricidal activity after the 5-weeks dosage was 
also seen. Azithromycin currently tested on its own did not show anti-
wolbachial activity in onchocerciasis. More trials to investigate the use of 
combinations are under way. 
Treatment should always be complemented with IVM to eliminate Mf from 
the skin and bring relief from any dermitis suffered by those with 
infection. However, the duration for doxycycline treatment is still longer 
than that desired for new antifilarial therapies suitable for mass 
application. It is noteworthy that a recent study in Cameroon 
demonstrated that even a 6-week treatment with doxycycline can be 
transferred to the responsibility of a village through community-directed 
treatment methods. These options should be followed with doxycycline 
treatment in filariasis endemic countries which require treatment options 
beyond available MDA, e.g. in areas with non-responsiveness of the 
parasite to MDA drugs and in areas with co-endemicity with loiasis. 
Treatment of bancroftian filariasis with doxycycline in combination with 
rifampicin is promising and was sufficient to mediate long-time reductions 
in Mf and also showed a moderate macrofilaricidal activity. 
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Doxycycline was also useful when looking at the insect vector of 
onchocerciasis. This was analyzed as part of this thesis with Wolbachia 
depleted Mf that could not develop into infective L3 in Simulium flies in 
the same proportions as in the placebo group after doxycycline treatment. 
The results demonstrate that doxycycline treatment can also decrease 
transmission rates by blocking/delaying larval development in the insect 
vector. 
Further results of this thesis complement establishment of PCR as a 
promising tool for detection of Brugia DNA in human plasma samples. This 
was the first study analyzed by real-time PCR for the HhaI gene including 
a large population in an endemic area with predominantly amicrofilaremic 
individuals. Definition of a threshold for HhaI measurement associated 
with active infection and the discrimination to larval exposure was 
determined based on PCR results. The results showed a high positive rate 
of samples with PCR which was highly sensitive even in Mf and IgG4 
negative samples.  
Finally a genetic association in brugian filariasis was shown by 
demonstrating an association of IL-18 and IL-4R SNPs with LE and 
microfilaremia, respectively. These analyses were just the beginning of a 
larger project analysing more than 90 SNPs in 1800 African patients 
infected with W. bancrofti, which just recently started. The knowledge of 
genomic associations in the different phenotypes and pathologies of LF 
could help to identifiy individuals at risk and lead to preventional 
interventions to avoid outcome of severe pathology. 
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APPENDIX I 
 
Primer Sequences  
  
Gene Sequence 5'-3' 
O. volvulus β-actin forward GTGCTACGTTGCTTTGGACT 
O. volvulus β-actin reverse GTAATCACTTGGCCATCAGG 
O. volvulus ftsZ forward AGGAATGGGTGGTGGTACTG 
O. volvulus ftsZ reverse CTTTAACCGCAGCTCTTGCT 
O. volvulus ftsZ hybridization probe CCTTGCCGCTTTCGCAATCAC 
  5'-Modification: 6-FAM 
  3'-Modification: Tamra 
murine IFN-γ forward TCAAGTGGCATAGATGTGGAAGAA 
murine IFN-γ reverse TGGCTCTGCAGGATTTTCATG 
W. bancrofti ftsZ forward  GCTTGGGCTTGAAGAATTACAAA 
W. bancrofti ftsZ reverse TCATTGGCAACCCTAAACAAGTT 
W. bancrofti ftsZ hybridiazation probe ACGTAGACACGCTTATTGTCATTCCAAACA 
  5'-Modification: 6-FAM 
  3'-Modification: Tamra 
W. bancrofti β-actin forward  CACTGGTGATGGTGTTACGC 
W. bancrofti β-actin reverse  GATTGCACCACAATTTCACG 
human β-actin forward  GATGAGATTGGCATGGCTTTA 
human β-actin reverse AACCGACTGCTGTCACCTTC 
Brugia HhaI forward GCAATATACGACCAGCAC 
Brugia HhaI reverse ACA*TTAGA*CAAGGAAATTGGTT 
  * indicates modified nucleotide 
Brugia HhaI QuantiProbe TTTTTAGTAGTTTTGGC 
  3'-Modification: 6-FAM 
  5'-Modification: Eclipse
TM Dark Quencher 
  5'-Modification: minor groove binder moiety 
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APPENDIX II 
 
In total 30 SNPs were analyzed for an association in LF. 
SNP rs Nummer 
VEGF -634 2010963 
VEGF -460 833061 
VEGF -634 2010963 
VEGF -1154 1570360 
Endothelin-1 5370 
TNFa -308 1800629 
IFNg 1861494 
INFg -3810 2069720 
IL-4R 1805010 
IL-4R 1049631 
IL-6 -174 1800795 
IL-6 -572 1800796 
TGFb Arg25Pro 1800471 
TGFb C509T 1800469 
TGFb Leu10Pro 1800470 
TGFb -G800A 1800468 
TLR2 Arg733Gln 5743708 
TLR4 Thr399Ile 4986791 
TLR4 Arg229Gly 4986790 
IL-18 -137 187238 
IL-18 -607 1946518 
VEGFR3 P1114L na 
TLR2 R677W na 
FLT4 -G857R na 
FLT4 -H1035R na 
FLT4 -L1044L na 
FLT4 -R1041P na 
IL-12 p40 na 
IL-13 na 
IL-12B na 
 na: not available in the public databases 
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APPENDIX III 
 
Calculation of the inbreeding coefficient F 
 
Calculation of the inbreeding coefficient F in a population is the analysis of 
a deviation from Hardy-Weinberg Equilibrium. The Hardy–Weinberg 
equilibrium (also termed as RUG, random union of gametes) states that 
both allele and genotype frequencies in a population remain constant; that 
is, they are in equilibrium from generation to generation unless specific 
disturbing influences are introduced. Those disturbing influences include 
non-random mating, mutations, selection, limited population size, 
"overlapping generations", random genetic drift and gene flow. It is 
important to understand that outside the lab, one or more of these 
"disturbing influences" are always in effect. This states that Hardy–
Weinberg equilibrium is impossible in nature. Genetic equilibrium is an 
ideal state that provides a baseline to measure genetic change. 
Static allele frequencies in a population across generations assume: 
random mating, no mutation (the alleles don't change), no migration or 
emigration (no exchange of alleles between populations), infinitely large 
population size, and no selective pressure for or against any traits. 
In the simplest case of a single locus with two alleles: the dominant allele 
is denoted A and the recessive a and their frequencies are denoted by p 
and q; freq (A) = p; freq (a) = q; p + q = 1. If the population is in 
equilibrium, then we will have freq (AA) = p2 for the AA homozygotes in 
the population, freq (aa) = q2 for the aa homozygotes, and freq 
(Aa) = 2pq for the heterozygotes. 
F (inbreeding coefficient) stays for the deviation from HWE (RUG) and is 
zero if a population is in equilibrium. If F>0, there is a heterozygous 
deficit, if F<0 a heterozygous overage.  
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Test of the inbreeding coefficient is important when looking at populations 
where HWE is likely to deviate from being in equilibrium. This is common 
in little populations where inbreeding occurs within family generations. 
 
F            relationship 
1           identical twins 
0.5 (½) full siblings 
0.5 (½) parent-offspring 
0.25 (¼) half siblings 
0.25 (¼) Uncle/Aunt-Niece/Nephew 
0.25 (¼) grandparent-grandchild 
0.125 (⅛)  cousins 
 
If F is 1 when looking at the genotypes of the analyzed population, blood 
sib ship or selection are the common explanations. For a genotype 
analysis only unrelated ancestors should be included. 
 
Figure A2.1 HWE-Equilibrium (RUG) 
 
P=genotypes    p=allel frequencies                      © T.F. Wienker 
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In the following is shown a manual test example for the calculation of F in 
a fictive population. This can also be done by using the deFinetti software 
created by Strom and Wienker (http://ihg.gsf.de/cgi-bin/hw/hwal.pl). 
 
In the example the analyzed population includes 157 individuals (N=157).  
The possible genotypes are:  
AA  Aa  aa 
Results of genotyping of the individuals show the numbers of genotypes 
(n) in the population: 
n AA=87 n Aa=50 n aa=20 N=157 
 
The genotype frequency (P) can be calculated: 
P AA= n AA/N =87/157=0.554 
P Aa =n Aa/N =50/157=0.318  
P aa =n aa/N =20/157=0.127 
       ∑=1 
These are the observed frequencies of the single genotypes in the 
population. 
 
With these numbers the allele frequency (p) can be calculated. This is the 
number (m) of allele a and allele A in the population. 
 
m A=2*n AA +n Aa 
m A=2*87+50 = 224 
 
m a=2*n aa +n Aa 
m a=2*20+50 = 90 
 
m a + m A =2 N (2*157)=314 
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allele frequencies (p): 
 
pA= mA /2N = 224/314 = 0.713 
pa= ma /2N =   90/314 = 0.287 
          ∑=1 
 
With the allele frequencies, the genotype frequency expectation in HWE 
(RUG) can be calculated. 
 
p A= m A /2N =0.713    m A=2*n AA +n Aa 
p a= m a /2N =0.287  m a=2*n aa +n Aa 
 
P AA = p A2 
P Aa = 2 p A* p a =2 m A /2N * m a /2N     2  
P aa = p a2 
 
Expected genotype in HWE (RUG) = 0.4093 
 
Observed genotype frequency: 0.3180 
Expected genotype frequency: 0.4093 
 
The difference between the observed genotype frequency and the 
expected genotype frequency in HWE (RUG) is described as factor k. 
Factor k is calculated by dividing the observed genotype frequency by the 
expected genotype frequency. 
 
k = 0.318 / 0.4083  
k = 0.0776 
 
 
 
 
2NAA+ nAa 
2N 
* 
2naa+ nAa 
2N 
factor: 1-F = k 
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Calculating the inbreeding coefficient F (deviation from HWE (RUG)), k is 
substracted from one. 
 
F = 1-k 
F = 1-0.0776 
F = 0.2231 
 
A heterozygous deficit is the usual situation found in nature. A 
heterozygous overage could account for selection or lab mistakes. A 
negative F value can account for an experimental error, if it is significant. 
Next step is to calculate if F (deviation from HWE (RUG)) is significant. If P 
is > 0.05, a scatter coincidence occurred.  
 
For testing the significance of the deviation from HWE (RUG), a X2 test 
(Pearson goodness-of-fit-chi-square) with one degree of freedom (1 df) is 
used. 
 
Table A 2.1 X2 test in the fictional population 
Allelfrequencies: 
p A = 0.713 
p a = 0.287 
 
NAA 
 
NAa 
 
Naa 
 
∑ 
observed 
frequencies 
87 50 20 157 
Expected 
frequencies N 
79.8 64.25 12.93 156,98 
Deviation 
Difference 
79.8-87 = 
- 7.2 
64.25-50 = 
14.25 
12.93-20 = 
- 7.07 
0 
Difference 2 51.84 203.06 49.98  
Difference 2 / 
Exp.Freq. N 
51.84/79.8= 
0.649 
203.06/64.25= 
3.160 
49.98/12.93= 
3.865 
7.674 
 
 
 
F=0  RUG 
F>0  heterozyg. deficit 
F<0  heterozyg. overage 
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Calculation of the expected genotype frequency N: 
NAa = N* PAa = N * 2 * PA * Pa 
     = 157 * 2 * 0.713 * 0.287 
    = 64.25 
NAA = N * PAA = N * PA
2 
       = 157 * 0.7132 
       = 79.8 
Naa = N * Paa = N * Pa
2 
     = 157 * 0.2872 
      = 12.93 
 
With the expected genotype frequencies, the difference to the observed 
genotype frequency is calculated. The squared difference divided by the 
expected genotype frequency results summarized for each genotype in the 
X2 value (here 7.674). 
The P value with 1 Df for this X2 value is >0.005 and <0.01.  
(http://de.wikibooks.org/wiki/Mathematik:_Statistik:_Tabelle_der_Chi-
Quadrat-Verteilung)  
In this fictive example, the deviation from HWE (RUG) is therefore 
significant. Selection, inbreeding or mutation could influence the 
population. 
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